P53-Y220C selective small-molecule reactivator compound, pharmaceutical composition and application of p53-Y220C selective small-molecule reactivator compound
By developing a specific compound to bind to the p53-Y220C mutant, the problems of high onset concentration and off-target effects of existing small molecule drugs were solved, and effective activation and tumor suppression of the p53-Y220C mutant were achieved.
Patent Information
- Application Number
- CN202410562025.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing small-molecule drugs are difficult to effectively and selectively bind to p53-Y220C mutants, resulting in high onset concentrations and possible off-target effects, which cannot effectively restore the wild-type conformation and transcriptional activity of p53 and inhibit tumors.
Develop a compound formula (I) and its racemates, stereoisomers, nitrogen oxides, solvates, polymorphs, metabolites, esters or pharmaceutically acceptable salts thereof by specific structures with p53 -Y220C mutant binds to stabilize the compound, restores the folded state and transcriptional activity of p53.
实现了对p53-Y220C突变体的有效激活,降低了肿瘤细胞的变性风险,恢复了p53的抑癌功能,提供了一种治疗含有p53-Y220C突变体肿瘤的潜在药物。
Smart Images

Figure CN118930488A_ABST
Abstract
Description
[0001] The present invention claims:
[0002] Priority to the prior application filed with the State Intellectual Property Office of China on May 11, 2023, with patent application number 202310530773.X and titled “p53-Y220C selective small molecule reactivator compounds, pharmaceutical compositions and uses thereof”;
[0003] The entirety of said prior application is incorporated herein by reference. Technical Field
[0004] The present invention belongs to the field of pharmaceutical compounds, and in particular relates to p53-Y220C selective small molecule reactivator compounds, pharmaceutical compositions and uses thereof. Background Art
[0005] Tumors are a collection of related diseases characterized by uncontrolled proliferation of tumor cells that may metastasize to all parts of the body. Tumor cell proliferation is inseparable from proto-oncogenes and tumor suppressor genes. Gene mutations can lead to abnormal activation or activity inhibition of the two, further promoting uncontrolled cell division. TP53, as a well-known tumor suppressor gene, is known as the "guardian of the genome." TP53 belongs to the p53-like transcription factor family, including three members, TP53, TP63 and TP73 genes, which encode three proteins, p53, p63 and p73, respectively. They are similar in structure: the DNA binding domains are almost identical, and both can bind to similar DNA-specific sequences to regulate the transcription of the same gene and some different genes; the C-terminal domains vary in size, sequence and function, regulating DNA binding and transcription, and mediating protein interactions; the N-terminal sequence encodes at least two different transcription activation domains. Similar to p53, p63 is also a key transcription factor that responds to DNA damage by inducing apoptosis, acting on the skull, face, limbs and central nervous system, and participating in the generation and regeneration of squamous cell epithelium throughout the body. p73 is required for the production of ciliated epithelial cells, which act on male germ cells, the immune system, the hearing system, the trachea, the lungs, the central nervous system, etc.
[0006] The p53 tumor suppressor factor is mainly distributed in the nucleoplasm of cells. As a receptor of cell stress, it can respond to a variety of cell stresses, including ultraviolet radiation, hypoxia, oncogene activation and DNA damage. After activation, p53 binds to a specific DNA sequence in a tetramer form, mediates downstream gene transcription, and inhibits cancer progression through a variety of mechanisms, such as including cell cycle regulation, apoptosis, aging, stem cell differentiation, metabolism (reducing sugar synthesis), ROS and mitochondria, DNA damage repair, etc. p53 can activate proteins involved in the above-mentioned pathways, including, for example, Fas / Apol, KILLER / DR5, Bax, Puma, Noxa, Bid, caspase-3, caspase6, caspase 7, caspase-8, caspase-9 and p21. In addition, p53 can also inhibit the transcription of a variety of genes, including c-MYC, Cyclin B, VEGF, RAD51, hTERT.
[0007] Due to its key role in tumor suppression, the TP53 gene is the most frequently mutated gene in human cancer, with p53 mutations present in nearly 50% of malignant tumors. In contrast to mutations in other tumor suppressor genes such as RB1, APC, PTEN, etc., most TP53 mutations are missense mutations, accounting for up to 75%. Missense mutations are mostly located in the DNA binding domain of p53, resulting in abnormal folding of the protein sequence required for DNA recognition and binding. There are many amino acid sites where p53 may mutate, such as Vall43, Hisl68, Argl75, Tyr220, Gly245, Arg248, Arg299, Phe270, Arg273, and Arg282. Accordingly, p53 mutations that can abolish wild-type p53 activity include, for example, R175H, Y220C, G245S, R248Q, R248W, R273H, and R282H. These p53 mutations can both distort the structure of the DNA binding site and destroy its thermodynamic stability. After TP53 mutation, the wild-type p53 tumor suppressor transcriptional activity is lost in the form of homozygous loss; in the form of heterozygous loss, it exhibits dominant negative effects, as well as gain of function effects such as increased binding to p63 and p73, thereby promoting tumor development. Therefore, mutant p53 proteins can be regarded as a group of heterogeneous proteins with different degrees of loss of normal tumor suppressor function and gain of oncogenic properties (GOF).
[0008] Although different p53 mutants have different activities, TP53 missense mutants can be regarded as proto-oncogenes, promoting tumor migration and drug resistance leading to poor prognosis, thus becoming therapeutic targets for drug development. Among them, the oncogenic p53 Y220C mutant exhibits a typical structure that is particularly suitable for the development of small molecule stabilizers. It is the ninth most common p53 missense mutation found in cancer, with approximately 100,000 new cancer cases worldwide each year. The mutation of Tyr220 to Cys forms a narrow hydrophobic cleft on the surface of the p53 DBD, thereby reducing its thermal stability by approximately 4 kcal / mol. Wild-type p53 is moderately stable and melts and denatures at 44°C, while the Y220C mutant protein rapidly unfolds and denatures from a folded state at body temperature under physiological conditions, effectively eliminating the tumor suppressor signal of the p53 wild type and driving tumorigenesis. Importantly, the hydrophobic cleft caused by the Y220C mutation is far away from the surface of the p53 protein involved in DNA recognition or protein interaction, allowing the development of small molecule drugs without interfering with its binding to the natural DNA substrate. The Y220C mutant is a temperature-sensitive mutant that binds to DNA at lower temperatures and denatures at body temperature. When a small molecule compound selectively binds to the p53-Y220C mutant, the compound can stabilize the Y220C mutant to reduce the possibility of p53 protein denaturation at body temperature, convert p53 from an unfolded state to a folded state, and restore the wild-type conformation and transcriptional activity of p53.
[0009] Studies have shown that several small molecules can bind to the hydrophobic cleft of the Y220C mutant, such as PK083, PK7088, PK5196, PC14586, etc., but the effective concentration is still high, so it cannot be ruled out whether it is an off-target effect. Therefore, it is still necessary to develop better small molecules to bind to the Y220C mutant more specifically, better restore the structure and transcriptional activity of the wild type of p53, and more effectively inhibit tumors. Summary of the invention
[0010] In order to solve the problems existing in the prior art, the present invention provides a compound represented by formula (I) and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt:
[0011]
[0012] in,
[0013] R1 and R2 are the same or different and are independently selected from H, deuterium, halogen, C 1-12 Alkyl, C 1-12 Alkoxy;
[0014] R3 is selected from H, deuterium, C1-12 alkyl;
[0015] X1 selected from NR x11 , CR x12 ;
[0016] X2 Selected from NR x21 , CR x22 , O, S;
[0017] X4 Selected from NR x41 , CR x42 , O, S;
[0018] R x11 , R x21 , R x41 does not exist; or R x11 , R x21 , R x41 The same or different, independently selected from H, C 1-12 Alkyl, halogenated C 1-12 Alkyl, C 3-12 Cycloalkyl;
[0019] R x12 , R x22 , R x42 are the same or different and are independently selected from H, halogen, cyano, aldehyde, carboxyl, C 1-12 Alkyl, C 2-12 Alkenyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, halogenated C 2-12 Alkenyl, halogenated C 1-12 Alkoxy, halogenated C 3-12 Cycloalkyl, -C(O)OC 1-12 Alkyl, -C(O)NH2;
[0020] X3 is selected from C or N;
[0021] represents a single or double bond;
[0022] Ring A is selected from C 6-14 Aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring;
[0023] Y is absent or selected from -C(=O)-R y1 、-S(=O)-R y2 、-S(=O)2-R y3 、-P(=O)(R y4 )(R y5 )、-S(=O)(=NR y6)-R y7 、-C(=O)NH-R y8 , R y9 Substituted 5-14 membered heteroaryl; R y1 , R y2 , R y3 , R y4 , R y5 , R y6 , R y7 , R y8 , R y9 are the same or different and are independently selected from H, deuterium, unsubstituted or optionally substituted by one, two or more R y Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 1-12 Alkyl-NH-, (C 1-12 alkyl)2N-, NH2; or, R y4 and R y5 and the P atom to which it is connected form an unsubstituted or optionally substituted with one, two or more R y substituted 3-14 membered heterocyclic group; or, R y6 and R y7 and the atoms to which they are attached form unsubstituted or optionally substituted with one, two or more R y substituted 3-14 membered heterocyclic group; or, R y7 The S atom to which it is connected forms a 3-14-membered heterocyclic group fused to ring A;
[0024] Each R y are the same or different and are independently selected from H, deuterium, halogen, cyano, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, -C(=O)-C 1-12 Alkyl, -C(=O)-C 3-12 Cycloalkyl;
[0025] Each R a are the same or different and are independently selected from H, deuterium, cyano, halogen, oxo (=O), unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, OH, NH2; each Ra1 are the same or different and are independently selected from H, deuterium, cyano, oxo (=O), halogen, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy;
[0026] m is selected from 0, 1, 2, 3, 4 or 5;
[0027] Or, Y and an R a The atoms to which they are attached form unsubstituted or optionally substituted with one, two or more R a1 substituted 3-14 membered heterocyclic group;
[0028] Z does not exist (i.e. R z directly bonded to X3) or selected from NH, O, S, CH2, CH2N (R z0 )、C(O)NH;R z0 Select from H or C 1-12 alkyl;
[0029] R z is selected from unsubstituted or optionally substituted with one, two or more R z1 Substituted with the following groups: C 1-12 Alkyl, C 6-14 Aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclic group, C 3-12 Cycloalkyl; each R z1 are the same or different and are independently selected from H, deuterium, OH, cyano, oxo (=O), halogen, unsubstituted or optionally substituted by one, two or more R z2 The following groups substituted: CH2=, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-14 membered heterocyclyl, NH2; each R z2 are the same or different and are independently selected from H, deuterium, OH, cyano, oxo (=O), halogen, unsubstituted or optionally substituted by one, two or more R z3 Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, S(O)2C 1-12 Alkyl, NH2; each R z3 are the same or different and are independently selected from H, deuterium, OH, cyano, oxo (=O), halogen, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, C1-12 Alkyl-NH-, (C 1-12 Alkyl)2N-, NH2.
[0030] According to some embodiments, R1, R2, and R3 are the same or different and are independently selected from H, C 1-6 alkyl.
[0031] According to some embodiments, R1, R2, and R3 are all H.
[0032] According to some embodiments, when X1 is selected from NR x11 When X2 is selected from CR x22 、N,X4 is selected from CR x42 , N; when X1 is selected from CR x12 When X2 is selected from N, O, S, and X4 is selected from N, S, O;
[0033] According to some embodiments, R x11 , R x21 , R x41 does not exist; or R x11 , R x21 , R x41 The same or different, independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl; R x12 , R x22 , R x42 are the same or different and are independently selected from H, cyano, halogen, carboxyl, aldehyde, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, cyano C 1-6 Alkyl, halogenated C 2-6 Alkenyl, C 3-8 Cycloalkyl, -C(O)OC 1-6 Alkyl, -C(O)NH2;
[0034] According to some embodiments, R x11 , R x21 , R x41 does not exist; or R x11 , R x21 , R x41 are the same or different and are independently selected from H, methyl, ethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl, cyano;
[0035] According to some embodiments, R x21 , R x41 Does not exist; R x11It is 2,2,2-trifluoroethyl.
[0036] According to some embodiments, R x12 , R x22 , R x42 are the same or different and are independently selected from H, methyl, ethyl, F, Cl, difluoromethyl, cyano, cyanomethylene, aldehyde, carboxyl, -C(O)OCH3, -C(O)NH2, 2,2,2-trifluoroethyl, cyclopropyl, vinyl,
[0037] According to some embodiments, R x12 is 2,2,2-trifluoroethyl; R x22 is selected from H, methyl, ethyl, F, Cl, aldehyde, difluoromethyl, cyano, cyanomethylene, -C(O)OCH3, -C(O)NH2; R x42 Selected from H, methyl, cyano, carboxyl, -C(O)OCH3, cyclopropyl, vinyl,
[0038] According to some embodiments, Ring A is selected from C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring, 5-10 membered heterocyclic ring;
[0039] According to some embodiments, ring A is selected from a benzene ring, a pyridine ring, a benzothiophene ring, a benzothiazole ring, a benzofuran ring, and a 2,3-dihydrobenzofuran ring.
[0040] According to some embodiments, ring A is selected from a benzene ring, a benzothiophene ring, a benzothiazole ring, a benzofuran ring, and a 2,3-dihydrobenzofuran ring.
[0041] According to some embodiments, Y is selected from -C(=O)-R y1 、-S(=O)-R y2 、-S(=O)2-R y3 、-P(=O)(R y4 )(R y5 )、-S(=O)(=NR y6 )-R y7 、-C(=O)NH-R y8 , R y9 Substituted 5-8 membered heteroaryl; R y1 , R y2 , R y3 , R y4 , R y5 , R y6 , R y7 , R y8 , R y9 are the same or different and are independently selected from H, unsubstituted or optionally substituted with one, two or more Ry Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, C 1-6 Alkyl-NH-, (C 1-6 alkyl)2N-, NH2; or, R y4 and R y5 and the P atom to which it is connected form an unsubstituted or optionally substituted with one, two or more R y Substituted 3-6 membered heterocycle;
[0042] According to some embodiments, each R y are the same or different and are independently selected from H, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-8 Cycloalkyl;
[0043] According to some embodiments, R y1 , R y2 , R y3 , R y4 , R y5 , R y6 , R y7 , R y8 , R y9 are the same or different and are independently selected from H, methyl, ethyl, isopropyl, cyclopropyl, methylamino, NH2, piperidinyl, tetrahydropyranyl, piperazinyl, cyanomethyl, 2,2,2-trifluoroethyl; or, R y4 and R y5 and the P atom to which it is connected form an unsubstituted or optionally substituted with one, two or more R y Replaced
[0044] According to some embodiments, each R y are the same or different and are independently selected from H, F, cyano, methyl, ethyl, methoxy, cyclopropyl, acetyl, cyclopropanecarboxyl;
[0045] According to some embodiments, Y is selected from
[0046] According to some embodiments, Y and one R aThe atoms to which they are attached form unsubstituted or optionally substituted with one, two or more R a1 Substituted 3-8 membered heterocycle; for example
[0047] According to some embodiments, each R a are the same or different and are independently selected from H, cyano, halogen, unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, OH, NH2; each R a1 are the same or different and are independently selected from H, cyano, oxo (=O), halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy;
[0048] According to some embodiments, each R a are the same or different and are independently selected from H, cyano, halogen, unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, OH, NH2; each R a1 are the same or different and are independently selected from H, cyano, oxo (=O), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy;
[0049] According to some embodiments, each R a are the same or different and are independently selected from fluorine, chlorine, methoxy, trifluoromethoxy, difluoromethoxy, monofluoromethoxy, cyclopropyloxy, difluoromethyl, trifluoromethyl,
[0050] According to some embodiments, m is selected from 1 or 2.
[0051] According to some embodiments, m is 1.
[0052] According to some embodiments, the ring is selected from a five-membered heteroaromatic ring containing at least one nitrogen atom. Those skilled in the art will appreciate that no two adjacent double bonds should exist in the ring.
[0053] According to some embodiments, the ring Selected from pyrazole ring, pyrrole ring, imidazole ring, thiazole ring, oxazole ring.
[0054] According to some embodiments, Z is absent or selected from NH, O, S, CH2, CH2N(CH3), C(O)NH, CH2NH.
[0055] According to some embodiments, R z is selected from unsubstituted or optionally substituted with one, two or more R z1 Substituted with the following groups: C 1-6 Alkyl, 5-10 membered heterocyclic group, C 5-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl;
[0056] According to some embodiments, R z is selected from unsubstituted or optionally substituted with one, two or more R z1 Substituted with the following groups: ethyl, propyl, phenyl, piperidinyl, cyclohexyl,
[0057] According to some embodiments, each R z1 are the same or different and are independently selected from hydrogen, F, Cl, methyl, methoxy, cyano, cyanomethyl, dimethylamino, oxo (=O), amino, methylamino, ethylamino, diethylamino, hydroxy, CH2=, CHF=, CF2=,
[0058] According to some embodiments, R z Selected from
[0059]
[0060] According to some embodiments, the compound represented by formula (I) has the structure shown below:
[0061]
[0062] Among them, ring A, Y, Z, R a , R z , R1, R2, R3, X1, X2, X3, X4, and m have the definitions described herein. According to some embodiments, the compound represented by formula (I) has the structure shown below:
[0063]
[0064] Among them, ring A, Y, Z, R a , Rz , R1, R2, R3, R 11 , R 12 , X2, X4, and m have the definitions described herein.
[0065] According to some embodiments, the compound represented by formula (I) has the structure shown below:
[0066]
[0067] Among them, Y, Z, R a , R z , R1, R2, R3, R 11 , R 12 , X2, X 4 , m have the definitions described herein.
[0068] According to some embodiments, the compound represented by formula (I) has the structure shown below:
[0069]
[0070] Among them, Z, R z , R1, R2, R3, R 11 , X2, have the definitions described in this article.
[0071] According to some embodiments, among the compounds represented by formula (I) and their racemates, stereoisomers, tautomers, nitrogen oxides, solvates, polymorphs, metabolites, esters, prodrugs or pharmaceutically acceptable salts, illustrative, non-limiting specific examples of the compounds represented by formula (I) are as follows:
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084] The present invention also provides a method for preparing the compound represented by formula (I), comprising the following steps:
[0085] (1) Compound 1 reacts with compound 2 to obtain compound 3;
[0086] (2) Compound 3 and R z -ZH reaction to obtain a compound represented by formula (I);
[0087]
[0088] Ring A, Y, Z, R a , R z , R1, R2, R3, X1, X2, X3, X4, m have the definitions described herein; L1 and L2 are selected from leaving groups, such as halogen, such as L1 is selected from Br, L2 is selected from Br.
[0089] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or a pharmaceutically acceptable salt thereof.
[0090] According to an embodiment of the present invention, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
[0091] According to an embodiment of the present invention, the pharmaceutical composition may further contain one or more other therapeutic agents.
[0092] The present invention also provides a method for treating tumor diseases, comprising administering to a patient a preventive or therapeutically effective amount of a compound represented by formula (I), its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or at least one of its pharmaceutically acceptable salts.
[0093] According to an embodiment of the present invention, the tumor is a tumor containing a p53-Y220C mutant.
[0094] The present invention also provides a method for treating tumor diseases, comprising administering to a patient an effective amount of the above pharmaceutical composition for prevention or treatment.
[0095] In some embodiments, the patient comprises a mammal, preferably a human.
[0096] The present invention also provides a compound represented by formula (I), at least one of its racemates, stereoisomers, tautomers, nitrogen oxides, solvates, polymorphs, metabolites, esters, prodrugs or pharmaceutically acceptable salts thereof for treating tumor diseases, or a pharmaceutical composition thereof.
[0097] The present invention also provides the use of at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof in the preparation of a drug.
[0098] According to an embodiment of the present invention, the use may be use in preparing anti-tumor drugs containing p53-Y220C mutants, such as use in preparing p53-Y220C reactivator drugs.
[0099] According to an embodiment of the present invention, the tumor containing the p53-Y220C mutant includes acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancer, AIDS-related lymphoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumors such as cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive cell tumor, neuroectodermal tumor, visual pathway and hypothalamic glioma, breast cancer, bronchial adenoma, Burkitt's lymphoma, unknown primary cancer, central nervous system lymphoma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive cell tumor, neuroectodermal tumor, visual pathway and hypothalamic glioma, breast cancer, bronchial adenoma, Burkitt's lymphoma, central nervous system lymphoma, cerebellar astrocytoma, etc. cell tumors, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelocytic leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, germ cell tumors, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gliomas, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular carcinoma, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, lip and oral cancer, liposarcoma, liver cancer, lung cancer such as non-small cell lung cancer and small cell Lung cancer, lymphoma, leukemia, macroglobulinemia, malignant bone fibrous histiocytoma / osteosarcoma, medulloblastoma, melanoma, mesothelioma, metastatic squamous cell carcinoma with occult primary, oral cancer, multiple endocrine neoplasms syndrome, myelodysplastic syndrome, myeloid leukemia, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma / malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer, pancreatic islet cell carcinoma, paranasal sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pine Astrocytoma, pineal germ cell tumor, pituitary adenoma, pleuropulmonary blastoma, plasmacytoma, primary central nervous system lymphoma, prostate cancer, colorectal cancer, renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer, Merkel cell carcinoma of the skin, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, laryngeal cancer, thymoma, thymic carcinoma, thyroid cancer, trophoblastic tumor (pregnancy), cancer of unknown primary site, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, and Wilms' tumor.
[0100] Beneficial Effects
[0101] The compound of the invention has good p53-Y220C mutant activation effect, can effectively restore the activity of p53-Y220C mutant protein, and is used for treating tumor diseases containing p53-Y220C mutant protein, as well as preparing medicines for such disorders or diseases.
[0102] Definition and explanation of terms
[0103] Unless otherwise specified, the definitions of groups and terms recorded in the specification and claims of this application, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in examples, etc., can be arbitrarily combined and combined with each other. The definitions of groups and compound structures after such combinations and combinations should be understood to be within the scope of the specification and / or claims of this application.
[0104] Unless otherwise specified, the numerical ranges recorded in this specification and claims are equivalent to recording at least each specific integer value therein. For example, the numerical range "1-14" is equivalent to recording each integer value in the numerical range "1-14", namely 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14.
[0105] The term "optional" (or "optionally", "optionally") in the general formula definitions of the present application means the situation of being substituted by zero, one or more substituents, for example, "optionally substituted by one, two or more R" means that it may not be substituted by R (unsubstituted) or may be selectively substituted by one, two or more R.
[0106] "More" means three or more.
[0107] The term "C 1-12 The term "alkyl" is understood to mean straight-chain and branched alkyl groups having 1 to 12 carbon atoms. 1-8 "Alkyl" means straight chain and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. 1-6 The term "alkyl" refers to straight-chain and branched alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, or the like or isomers thereof.
[0108] “C 2-12 "Alkenyl" is understood to mean preferably a linear or branched monovalent hydrocarbon radical containing one or more double bonds and having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, more preferably "C 2-8 "C2-8 The term "alkenyl" is understood to mean preferably a linear or branched monovalent hydrocarbon radical containing one or more double bonds and having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, for example, having 2, 3, 4, 5 or 6 carbon atoms (i.e., C 2-6 alkenyl), having 2 or 3 carbon atoms (i.e., C 2-3 It is understood that where the alkenyl group contains more than one double bond, the double bonds may be separated from one another or conjugated. The alkenyl group is, for example, vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, (E)-but-2-enyl, (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, pent-4-enyl, (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl, (Z)-pent-2-enyl, (E)- Pent-1-enyl, (Z)-pent-1-enyl, hex-5-enyl, (E)-hex-4-enyl, (Z)-hex-4-enyl, (E)-hex-3-enyl, (Z)-hex-3-enyl, (E)-hex-2-enyl, (Z)-hex-2-enyl, (E)-hex-1-enyl, (Z)-hex-1-enyl, isopropenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl , 2-methylprop-1-enyl, (E)-1-methylprop-1-enyl, (Z)-1-methylprop-1-enyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, (E)-2-methylbut-2-enyl, (Z)-2-methylbut-2-enyl, (E)-1-methylbut-2-enyl, (Z)-1-methyl but-2-enyl, (E)-3-methylbut-1-enyl, (Z)-3-methylbut-1-enyl, (E)-2-methylbut-1-enyl, (Z)-2-methylbut-1-enyl, (E)-1-methylbut-1-enyl, (Z)-1-methylbut-1-enyl, 1,1-dimethylprop-2-enyl, 1-ethylprop-1-enyl, 1-propylvinyl, 1-isopropylvinyl.
[0109] The term "C 1-12 "Alkoxy" is understood to mean "C 1-12 Alkyl-O-", C 1-12 Alkyl is as defined above.
[0110] The term "C 3-12 The term "cycloalkyl" shall be understood as a saturated or partially saturated monovalent monocyclic, bicyclic (such as condensed, bridged, spiro) or tricyclic hydrocarbon group having 3 to 12 carbon atoms, preferably "C 3-10 Cycloalkyl", more preferably "C 3-8 The term "C 3-12The term "cycloalkyl" is understood to mean a saturated or partially saturated monovalent monocyclic, bicyclic (e.g. bridged, spiro) or tricyclic hydrocarbon radical having 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, wherein the carbon atoms are all single-bonded or partially single-bonded, partially double-bonded and / or triple-bonded. 3-12 The cycloalkyl group may be a monocyclic hydrocarbon group, for example a monocyclic alkyl group, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic hydrocarbon group, such as borneol, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, 2,7-diazaspiro[3,5]nonanyl, 2,6-diazaspiro[3,4]octanyl, or a tricyclic hydrocarbon group, such as adamantyl.
[0111] The term "C 3-12 "Cycloalkyl" is understood to be a saturated monovalent monocyclic, bicyclic (such as fused ring, bridged ring, spiro ring) or tricyclic alkyl group having 3 to 12 carbon atoms, preferably "C 3-10 Cycloalkyl", more preferably "C 3-8 The term "Cycloalkyl" 3-12 "Cycloalkyl" is understood to be a saturated monovalent monocyclic, bicyclic (eg bridged, spiro) or tricyclic alkyl group having 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, wherein the carbon atoms are all singly bonded. 3-12 The cycloalkyl group may be a monocyclic alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic alkyl group such as borneol, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, 2,7-diazaspiro[3,5]nonanyl, 2,6-diazaspiro[3,4]octanyl, or a tricyclic hydrocarbon group such as adamantyl.
[0112] The term "C 6-14 "Aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring having 6 to 14 carbon atoms, which may be a single aromatic ring or a polyaromatic ring fused together, preferably "C 6-10 The term "C 6-14 The term "aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring ("C 6-14or a ring having 9 carbon atoms ("C9 aryl"), for example indanyl or indenyl, or a ring having 10 carbon atoms ("C 10 aryl), such as tetrahydronaphthyl, dihydronaphthyl or naphthyl, or a ring having 13 carbon atoms ("C 13 aryl), such as fluorenyl, or a ring having 14 carbon atoms ("C 14 aryl”), such as anthracenyl. When the C 6-20 When the aryl group is substituted, it may be monosubstituted or polysubstituted. Also, there is no limitation on the substitution position, for example, it may be substituted at the ortho position, para position or meta position.
[0113] The term "5-14 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic (e.g. fused, bridged, spiro) or tricyclic aromatic ring systems having 5 to 14 ring atoms and containing 1 to 5 heteroatoms independently selected from N, O and S, for example "5-10 membered heteroaryl". The term "5-14 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 5 or 6 or 9 or 10 carbon atoms, and containing 1 to 5, preferably 1 to 3 heteroatoms each independently selected from N, O and S and, in each case, furthermore, may be benzo-fused. "Heteroaryl" also refers to a radical in which a heteroaromatic ring is fused to one or more aryl, alicyclic or heterocyclyl rings, wherein the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl, 1-, 3-, 4- , 5-, 6-, 7- or 8-isoquinolyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl, 2-, 3-, 4-, 5- or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 6- or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-4aHcarbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8- 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbozolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-phenanthridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-pyridinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10-phenanthrolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9- 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9- or 10-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9- or 10-phenazinyl, 2-, 3-, 4-, 5-, 6- or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-benzoisoquinolyl, 2-, 3-, 4- or thieno[2,3-b]furanyl, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10- or 11-7H-pyrazino[2,3-c]carbazolyl, 2-, 3-, 5-, 6- or 7-2H-furo[3,2-b]pyranyl, 2-, 3-, 4-, 5-, 7- or 8-5H-pyrido[2,3-d]-oxazinyl, 1-, 3- or 5-1H-pyrazolo[4,3-d]oxazolyl, 2-, 4- or 54H-imidazo[4,5-d]thiazolyl, 3-, 5- or 8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5- or 6-imidazo[2,1-b]thiazolyl, 1-, 3-, 6-, 7-, 8- or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10 or 11-4H-pyrido[2,3 1-, 2-, 3-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-, or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-4H-pyrrolo[1,2-b][2]benzazepinyl. Typical fused heteroaryl groups include, but are not limited to, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, and 2-, 4-, 5-, 6-, or 7-benzothiazolyl. When the 5-14 membered heteroaryl group is connected to other groups to form the compound of the present invention, it can be a carbon atom on the 5-14 membered heteroaryl ring connected to other groups, or it can be a heteroatom on the 5-14 membered heteroaryl ring connected to other groups. When the 5-14 membered heteroaryl group is substituted, it can be monosubstituted or polysubstituted. Furthermore, there is no limitation on the substitution site, for example, the hydrogen bonded to the carbon atom on the heteroaryl ring may be substituted, or the hydrogen bonded to the heteroatom on the heteroaryl ring may be substituted.
[0114] Unless otherwise defined, the term "3-14 membered heterocyclyl" refers to a saturated or unsaturated non-aromatic ring or ring system, for example, it is a 4-, 5-, 6- or 7-membered monocyclic ring, a 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic ring (such as a fused ring, a bridged ring, a spirocyclic ring) or a 10-, 11-, 12-, 13- or 14-membered tricyclic ring system, and contains at least one, for example 1, 2, 3, 4, 5 or more heteroatoms selected from O, S and N, wherein N and S may also be optionally oxidized to various oxidation states to form nitrogen oxides, -S(O)- or -S(O)2- states. Preferably, the heterocyclyl may be selected from "3-10 membered heterocyclyl". The term "3-10 membered heterocyclyl" means a saturated or unsaturated non-aromatic ring or ring system, and contains at least one heteroatom selected from O, S and N. The heterocyclic group can be connected to the rest of the molecule by any one of the carbon atoms or the nitrogen atom (if present). The heterocyclic group can include fused or bridged rings and spirocyclic rings. In particular, the heterocyclic group can include but is not limited to: 4-membered rings, such as azetidinyl, oxetanyl; 5-membered rings, such as tetrahydrofuranyl, dihydrofuranyl, dioxolyl, pyrrolidinyl, dihydropyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or 6-membered rings, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianyl; or 7-membered rings, such as diazepanyl. Optionally, the heterocyclic group can be benzo-fused. The heterocyclyl group may be bicyclic, for example, but not limited to, a 5,5-membered ring, such as a hexahydrocyclopenta[c]pyrrol-2(1H)-yl ring, or a 5,6-membered bicyclic ring, such as a hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl ring. "Heterocyclyl" also refers to a group in which a heterocycle is fused to one or more aryl, alicyclic or heterocyclyl rings, wherein the radical or point of attachment is on the heterocycle. The heterocyclic group may be partially unsaturated, i.e., it may contain one or more double bonds, such as but not limited to dihydrofuranyl, dihydropyranyl, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 1,2,3,5-tetrahydrooxazolyl or 4H-[1,4]thiazinyl, or it may be benzo-fused with a 5-membered ring or a 6-membered ring containing at least one heteroatom selected from O, S and N, wherein the specific 5-membered ring or the 6-membered ring is as described above, and specific examples include but are not limited to dihydroisoquinolyl, dihydrobenzofuranyl, dihydrobenzopyrrolyl. When the 3-14-membered heterocyclic group is connected to other groups to form the compound of the present invention, the carbon atoms on the 3-14-membered heterocyclic group may be connected to other groups, or the heterocyclic atoms on the 3-14-membered heterocyclic group may be connected to other groups. For example, when the 3-14-membered heterocyclic group is selected from piperazinyl, the nitrogen atom on the piperazinyl may be connected to other groups. Or when the 3-14 membered heterocyclic group is selected from piperidinyl, the nitrogen atom on the piperidinyl ring and the carbon atom at the para position thereof may be connected to other groups.
[0115] The term "spirocyclic" refers to a ring system in which two rings share one ring-forming atom.
[0116] The term "fused ring" refers to a ring system in which two rings share two ring atoms.
[0117] The term "bridged ring" refers to a ring system in which two rings share three or more ring atoms.
[0118] The term "halogen" refers to fluorine, chlorine, bromine and iodine.
[0119] "Halo" means substituted with one or more halogens.
[0120] In the present invention, the compounds involved also include isotopically labeled compounds, which are the same as those shown in Formula I, but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number usually occurring in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of H, C, N, O, S, F and Cl, such as 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 32 P. 35 S. 18 F and 36 Cl. Compounds of the invention, prodrugs thereof, or pharmaceutically acceptable salts of said compounds or said prodrugs containing the above-mentioned isotopes and / or other isotopes of other atoms are within the scope of the invention. Certain isotopically labeled compounds of the invention, for example, those incorporating radioactive isotopes (such as 3 H and 14 C) compounds can be used in drug and / or substrate tissue distribution assays. 3 H) and carbon 14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. 2 H or D) substitution may provide certain therapeutic advantages derived from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and may therefore be preferred in certain circumstances. The presence of hydrogen in the substituents of the present invention without the separate listing of the term deuterium or tritium does not exclude deuterium or tritium, but may also include deuterium or tritium.
[0121] In the chemical structure of the compound described in the present invention, the bond Indicates that the configuration is not specified. Indicates the absolute configuration, that is, if there are stereoisomers in the chemical structure, the bond Can be or include both Two configurations.
[0122] Those skilled in the art will appreciate that the compounds of formula (I) may exist in the form of various pharmaceutically acceptable salts. If these compounds have a basic center, they may form acid addition salts; if these compounds have an acidic center, they may form a base addition salt; if these compounds contain both an acidic center (e.g., a carboxyl group) and a basic center (e.g., an amino group), they may also form an inner salt.
[0123] The compounds of the present invention may exist in the form of solvates (e.g. hydrates), wherein the compounds of the present invention contain polar solvents as structural elements of the crystal lattice of the compounds, in particular water, methanol or ethanol. The amount of polar solvents, in particular water, may exist in a stoichiometric or non-stoichiometric ratio.
[0124] According to its molecular structure, the compounds of the present invention may be chiral, and therefore various enantiomeric forms may exist. Thus, these compounds may exist in racemic form or optically active form. The compounds of the present invention encompass isomers or mixtures, racemates in which each chiral carbon is in R or S configuration. The compounds of the present invention or their intermediates can be separated into enantiomeric compounds by chemical or physical methods known to those skilled in the art, or used in this form for synthesis. In the case of racemic amines, diastereomers are prepared from the mixture by reaction with an optically active resolution agent. Examples of suitable resolution agents are optically active acids, such as tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g., N-benzoylproline or N-phenylsulfonylproline) or various optically active camphorsulfonic acids in R and S forms. Chromatographic enantiomer resolution can also be advantageously carried out with the aid of optically active resolving agents such as dinitrobenzoylphenylglycine, cellulose triacetate or other carbohydrate derivatives or chiral derivatized methacrylate polymers immobilized on silica gel. Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, for example, hexane / isopropanol / acetonitrile.
[0125] The corresponding stable isomers can be separated according to known methods, for example by extraction, filtration or column chromatography.
[0126] The term "patient" refers to any animal including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses or primates, and most preferably humans.
[0127] The term "therapeutically effective amount" refers to the amount of an active compound or drug that elicits the biological or medical response that a researcher, veterinarian, physician or other clinician is seeking in a tissue, system, animal, individual or human, and includes one or more of the following: (1) Preventing disease: e.g., preventing a disease, disorder or condition in an individual who is susceptible to the disease, disorder or condition but does not yet experience or develop the pathology or symptoms of the disease. (2) Inhibiting disease: e.g., inhibiting a disease, disorder or condition (i.e., preventing further development of the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder or condition. (3) Alleviating disease: e.g., alleviating a disease, disorder or condition (i.e., reversing the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder or condition. DETAILED DESCRIPTION
[0128] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0129] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0130] The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or / and liquid chromatography-mass spectrometry (LC-MS). The NMR chemical shift (δ) is given in parts per million (ppm). The NMR measurement is performed using a Bruker AVANCE-400 nuclear magnetic spectrometer, the measurement solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD) or deuterated chloroform (CDCl3), and the internal standard is tetramethylsilane (TMS).
[0131] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 1200 Infinity Series mass spectrometer, and HPLC was performed using an Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150×4.6 mm column).
[0132] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao Ocean Chemical GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0133] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods. Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring, in a dry nitrogen or argon atmosphere, with a dry solvent, and the reaction temperature is in degrees Celsius.
[0134] Example 1
[0135]
[0136] Step 1: Synthesis of Compound 001-2
[0137] To a solution of 3,5-dibromo-1H-pyrazole (compound 001-1, 5 g, 22.137 mmol, 1 equiv) in N,N-dimethylformamide (10 mL) were added potassium carbonate (9.18 g, 66.411 mmol, 3 equiv) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (10.28 g, 44.274 mmol, 2 equiv), and the mixture was stirred at room temperature for 2 hours. After the reaction, the reaction mixture was quenched by adding water at room temperature, extracted with ethyl acetate (3×100 mL), the organic phases were combined, backwashed with saturated brine (3×50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give compound 001-2 (4.0 g).
[0138] 1 H NMR (400MHz, DMSO-d6) δ6.85 (t, J = 1.4Hz, 1H), 5.18 (q, J = 8.8Hz, 2H).
[0139] Step 2: Synthesis of Compound 001-3
[0140] At room temperature, 3,5-dibromo-1-(2,2,2-trifluoroethyl)pyrazole (compound 001-2, 700 mg, 2.273 mmol, 1 equiv) and 3-methoxy-N-methyl-4-propyl-2-alkynylaminobenzamide (compound 001-2A, 545.82 mg, 2.500 mmol, 1.1 equiv) were dissolved in dimethyl sulfoxide (5 mL), and cuprous iodide (43.30 mg, 0.227 mmol, 0.1 equiv) was added. ), triethylamine (690.19 mg, 6.819 mmol, 3 equiv), nitrogen protection, reaction at 50 ° C for 2 hours. After the reaction, the reaction mixture was cooled to room temperature and extracted with ethyl acetate (3×20 mL). The organic phases were combined and backwashed with saturated brine (1×20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane / methanol=10:1) to give compound 001-3 (105 mg, 9.34%).
[0141] LCMS: (ESI, m / z): 445.00 [M+H] + .
[0142] Step 3: Synthesis of Compound 1
[0143] To a solution of 4-(3-[5-bromo-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]propyl-2-ynyl-1-amino)-3-methoxy-N-methylbenzamide (compound 001-3, 50 mg, 0.112 mmol, 1 equiv) and 1-methylpiperidin-4-amine (14.11 mg, 0.123 mmol, 1.1 equiv) in dioxane (2 mL) were added cesium carbonate (109.77 mg, 0.336 mmol, 3 equiv) and (SP-4-1)-[1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(2-methylpyridine)palladium (9.45 mg, 0.011 mmol, 0.1 equiv) at room temperature. Under nitrogen protection, the reaction was stirred at 100°C overnight. After the reaction was completed, the reaction mixture was quenched with water at room temperature, extracted with ethyl acetate (3×5 mL), the organic phases were combined, backwashed with saturated brine (1×20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions: (chromatographic column specifications: Xselect CSHTM Prep C18, 5μm, 19×150mm; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 5% B to 30% B in 8 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 6.72) to obtain the formate salt of compound 1.
[0144] LCMS: (ESI, m / z): 479.20 [M+H] + .
[0145] 1 H NMR (400MHz, DMSO-d6) δ8.23 (s, 1H), 8.09 (q, J = 4.4Hz, 1H), 7.39 (dd, J = 8.2, 1.8Hz, 1H), 7.3 3(d,J=1.9Hz,1H),6.70(d,J=8.2Hz,1H),5.95(t,J=6.3Hz,1H),5.72(s,1H),5.41(d,J=7.7 Hz,1H),4.68(q,J=8.9Hz,2H),4.26(d,J=6.3Hz,2H),3.83(s,3H),3.14(m,1H),2.86-2.65( m,5H),2.22(s,3H),2.10(t,J=11.1Hz,2H),1.85(dd,J=13.1,3.7Hz,2H),1.45–1.36(m,2H).
[0146] Using conditions similar to those in the above examples, the compounds listed in Table 1 were prepared. The structural characterization data of these compounds are listed in Table 1.
[0147] Table 1
[0148]
[0149]
[0150] Example 2
[0151]
[0152] Step 1: Synthesis of compounds 2-A and 2-B
[0153] To a solution of 4-(3-[5-bromo-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]propyl-2-ynyl-1-amino)-3-methoxy-N-methylbenzamide (compound 001-3, 50 mg, 0.112 mmol, 1 equiv) and N,N-dimethylcyclohexane-1,4-diamine (19.17 mg, 0.134 mmol, 1.2 equiv) in dioxane (2 mL) were added (SP-4-1)-[1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(2-methylpyridine)palladium (7.14 mg, 0.011 mmol, 0.1 equiv) and cesium carbonate (109.77 mg, 0.336 mmol, 3 equiv) at room temperature, respectively. The reaction was stirred at 100 ° C under nitrogen protection for 2 hours. After the reaction was completed, the reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate (3×5 mL), the organic phases were combined, backwashed with saturated brine (1×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions: (chromatographic column specifications: Column: Sunfire C18, 5μm, 30mm×150mm; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 5% B to 27% B in 10 minutes; detection wavelength: 254nm / 221nm; retention time (minutes): 8.9 / 9.55) to obtain the formate salt of compound 2-A (7.9 mg, 99.23%) and the formate salt of compound 2-B (1.3 mg, 99.23%).
[0154] Compound 2-A, retention time 8.9 minutes.
[0155] LCMS: (ESI, m / z): 507.20 [M+H] + .
[0156] 1 H NMR (400MHz, DMSO-d6) δ8.23(d,J=5.0Hz,1H),8.09(t,J=4.7Hz,1H),7.39(dd,J=8.2,1.8Hz,1H),7.33 (d,J=1.9Hz,1H),6.70(d,J=8.2Hz,1H),5.95(t,J=6.3Hz,1H),5.71(s,1H),5.30(d,J=7.8Hz,1H),4.67 (q,J=8.8Hz,2H),4.26(d,J=6.3Hz,2H),3.83(s,3H),3.04(m,2H),2.75(d,J=4.4Hz,3H),2.21(d,J=5.6 Hz, 6H), 1.98 (d, J = 12.4Hz, 2H), 1.77 (d, J = 11.9Hz, 2H), 1.22 (q, J = 12.6Hz, 2H), 1.07 (q, J = 11.7Hz, 2H).
[0157] Compound 2-B, retention time 9.55 minutes.
[0158] LCMS: (ESI, m / z): 507.30 [M+H] + .
[0159] 1 H NMR (400MHz, DMSO-d6) δ8.22(d,J=6.9Hz,1H),8.09(t,J=4.7Hz,1H),7.39(dd,J=8.3, 1.9Hz,1H),7.34(d,J=1.8Hz,1H),6.70(d,J=8.3Hz,1H),5.95(t,J=6.3Hz,1H),5.73( s,1H),5.50–5.45(m,1H),4.67(q,J=8.9Hz,2H),4.26(d,J=6.3Hz,2H),3.83(s,3H),3 .26(m,2H),2.75(d,J=4.4Hz,3H),2.27(s,6H),1.78-1.56(m,4H),1.52–1.37(m,4H).
[0160] Using conditions similar to those in the above examples, the compounds listed in Table 2 were prepared. The structural characterization data of these compounds are listed in Table 2.
[0161] Table 2
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173] Example 3
[0174]
[0175] Step 1: Synthesis of Compound 144-1
[0176] Under nitrogen protection, to a solution of 4-({3-[5-bromo-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]propyl-2-ynyl-1-amino)-3-methoxy-N-methylbenzamide (compound 001-3, 600 mg, 1.348 mmol, 1 equiv) and 4-aminocyclohexane-1-one (182.99 mg, 1.618 mmol, 1.2 equiv) in 1,4-dioxane (9.0 mL) at room temperature, cesium carbonate (2.20 g, 6.740 mmol, 5 equiv) and (SP-4-1)-[1, 3-Bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(2-methylpyridine)palladium (113.35 mg, 0.135 mmol, 0.1 equiv), stirring was continued at 100°C overnight. After the reaction was completed, methanol (4.0 mL) was added to the reaction mixture at room temperature to quench it. The residue was concentrated under reduced pressure and purified by reverse phase column chromatography under the following conditions (40 g, C18 chromatography column, mobile phase: water (0.1% ammonium bicarbonate) and acetonitrile, gradient: 5% to 60% in 30 minutes, detection wavelength: UV 254 nm) to obtain compound 144-1 (350 mg, 54.39%).
[0177] LCMS: (ESI, m / z): 477.20 [M+H] + .
[0178] Step 2: Synthesis of compound 144
[0179] Under nitrogen protection, glacial acetic acid (12.58 mg, 0.209 mmol, 1 equiv) was added to a solution of 3-methoxy-N-methyl-4-[(3-{5-[(4-oxocyclohexyl)amino]-2-(2,2,2-trifluoroethyl)pyrazol-3-yl}propyl-2-yn-1-yl)amino]benzamide (compound 144-1, 100 mg, 0.209 mmol, 1 equiv) in thiomorpholine (1.0 mL) at room temperature, and the reaction was stirred at room temperature for 2 hours. After one hour, sodium cyanoborohydride (65.8 mg, 1.045 mmol, 5 equiv) was added at room temperature. After the addition was completed, the system was stirred at 50°C for 3 hours. After the reaction was completed, water (10 mL) was added to the reaction mixture at room temperature to quench it, and it was extracted with ethyl acetate (3×20 mL). The organic phases were combined, backwashed with saturated brine (3×20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions (chromatographic column specifications: YMC Triart C18 ExRs 5μm, 30mm×150mm; mobile phase A: water (10 mmol per liter of ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 30% B to 75% B in 8 min; detection wavelength: UV 254nm / 220nm; retention time (minutes): 6.4) to obtain compound 144 (10.58 mg, 8.53%).
[0180] LCMS: (ESI, m / z): 564.25 [M+H] + .
[0181] Using conditions similar to those in the above examples, the compounds listed in Table 3 were prepared. The structural characterization data of these compounds are listed in Table 3.
[0182] Table 3
[0183]
[0184]
[0185]
[0186]
[0187]
[0188] Example 4
[0189]
[0190] Step 1: Synthesis of compound 46
[0191] To a solution of 3-methoxy-N-methyl-4-{[3-(5-{[4-(thiomorpholin-4-yl)cyclohexyl]amino}-2-(2,2,2-trifluoroethyl)pyrazol-3-yl)propyl-2-yn-1-yl]amino}benzamide (compound 144, 80 mg, 0.142 mmol, 1 equiv) in dichloromethane (3 mL) was added 3-chloroperbenzoic acid (73.34 mg, 0.426 mmol, 3 equiv) at 0°C. After the addition was completed, the system was naturally warmed up and stirred for 2 hours. After the reaction was completed, the reaction mixture was quenched by adding saturated aqueous sodium carbonate solution (5 mL) at room temperature, extracted with ethyl acetate (3×15 mL), the organic phases were combined, backwashed with saturated brine (3×10 mL), dried over anhydrous sodium sulfate, and the residue was concentrated under reduced pressure to give compound 46 (crude). The crude compound 46 was purified by HPLC under the following conditions: (chromatographic column specifications: YMC Triart C18 ExRs 5 μm, 30 mm×150 mm; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 15% B to 42% B in 10 min; detection wavelength: UV 254 nm / 220 nm) to obtain compounds 46-A (2.33 mg, 2.68%) and 46-B (2.28 mg, 2.59%).
[0192] Compound 46-A
[0193] LCMS: (ESI, m / z): 596.24 [M+H] + .
[0194] 11H NMR (400 MHz, DMSO-d6, ppm) δ 8.09 (d, J = 4.6 Hz, 1H), 7.39 (dd, J = 8.2, 1.8 Hz, 1H), 7.33 (d, J = 1.8 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 5.95 (t, J = 6.3 Hz, 1H), 5.72 (s, 1H), 5.38 (d, J = 8.0 Hz, 1H), 4.69 (q, J = 8.8 Hz, 2H), 4.26 (d, J = 6.3 Hz, 2H), 3.83 (s, 3H), 3.79 (d, J = 12.0 Hz, 2H), 3.54 (t, J = 12.4 Hz, 2H), 3.19–3.07 (m, 1H), 3.00 (t, J = 11.9 Hz, 1H), 2.90 (d, J = 11.9 Hz, 2H), 2.78 (d, J = 13.7 Hz, 2H), 2.75 (d, J = 4.5 Hz, 3H), 2.35 (s, 2H), 2.09 (d, J = 12.5 Hz, 2H), 1.57 (q, J = 12.0 Hz, 2H), 1.15 (q, J = 12.2 Hz, 2H).
[0195] Compound 46-B
[0196] LCMS: (ESI, m / z): 596.24 [M+H] + .
[0197] 1 1H NMR (400 MHz, DMSO-d6, ppm) δ 8.09 (d, J = 4.5 Hz, 1H), 7.41–7.37 (m, 1H), 7.34 (d, J = 1.8 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 5.95 (t, J = 6.3 Hz, 1H), 5.76 (s, 1H), 5.65 (d, J = 7.3 Hz, 1H), 4.68 (q, J = 8.8 Hz, 2H), 4.26 (d, J = 6.3 Hz, 2H), 3.83 (s, 5H), 3.62–3.49 (m, 3H), 2.98 (t, J = 12.2 Hz, 1H), 2.83 (dd, J = 24.3, 12.7 Hz, 4H), 2.75 (d, J = 4.5 Hz, 3H), 2.13 (d, J = 11.8 Hz, 2H), 1.93 (d, J = 13.5 Hz, 2H), 1.75 (q, J = 12.0 Hz, 2H), 1.47 (t, J = 13.2 Hz, 2H).
[0198] Example 5
[0199]
[0200] Step 1: Synthesis of compound 17-2
[0201] At room temperature, tert-butyl 2-oxo-6-azaspiro[3.5]nonane-6-carboxylate (300 mg, 1.254 mmol, 1 equiv), 4-({3-[3-amino-2-(2,2,2-trifluoroethyl)1H-pyrazol-5-yl]propyl-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide (compound 17-1, 573.68 mg, 1.505 mmol, 1.2 equiv) and N,N-dimethylformamide (4 mL) were added to an 8 mL sample vial. The temperature was lowered to 0°C, and trimethylsilyl chloride (340.47 mg, 3.135 mmol, 2.5 equiv) and 1M borane tetrahydrofuran complex (1.254 mL, 1.254 mmol, 1 equiv) were added. The reaction was continued to stir at 0°C for 1 hour. After the reaction was completed, the reaction mixture was quenched with water at room temperature, and the reaction mixture was extracted with ethyl acetate (3 x 10 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (1:1)) to give compound 17-2 (210 mg, 27.70%).
[0202] LCMS: (ESI, m / z): 605.30 [M+H] + .
[0203] Step 2: Synthesis of compound 17-3
[0204] At room temperature, 2-{[5-(3-{[2-methoxy-4-(methylcarbamoyl)phenyl]amino}propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)1H-pyrazol-3-yl]amino}-6-azaspiro[3.5]nonane-6-carboxylic acid tert-butyl ester (Compound 17-2, 300 mg, 0.496 mmol, 1 equiv), dichloromethane (3 mL) and trifluoroacetic acid (3 mL) were added to the sample bottle and stirred for 2 hours. After the reaction was completed, the residue was concentrated in vacuo to give Compound 17-3 (200 mg, 79.90%).
[0205] LCMS: (ESI, m / z): 505.15 [M+H] + .
[0206] Step 2: Synthesis of compounds 17-A and 17-B
[0207] At room temperature, 4-{[3-(5-{6-azaspiro[3.5]non-2-ylamino}-2-(2,2,2-trifluoroethyl)1H-pyrazol-3-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide (compound 17-3, 100 mg, 0.198 mmol, 1 equiv), methanol (2 mL), acetic acid (0.2 mL), formaldehyde (5.95 mg, 0.198 mmol, 1 equiv) and sodium cyanoborohydride (24.91 mg, 0.396 mmol, 2 equiv) were added to the sample bottle and stirred at 50 ° C for 1 hour. After the reaction was completed, the reaction mixture was cooled to room temperature, quenched with water, and the aqueous phase was extracted with ethyl acetate (3x 30mL), the organic phase was washed with saturated brine (1x50mL), dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain compound 17, which was dissolved in methanol and sent for preparation under the following conditions: (chromatographic column specifications: XSelect CSH Fluoro Phenyl 5m, 30mm*150mm; mobile phase A: water (0.1% ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 ml per minute; elution gradient: 10% B to 35% B in 8 minutes; detection wavelength: UV254nm / 220nm; retention time (minutes): 7.23), there was isomerization after freeze-drying, and secondary preparation was performed, and the chromatography column specifications (XSelect CSH Fluoro Phenyl 5μm, 30mm*150mm; mobile phase A: water (0.1% trifluoroacetic acid), mobile phase B: acetonitrile; flow rate: 60 ml per minute; elution gradient: 15% B to 35% B in 8 minutes; detection wavelength: UV 254nm / 220nm; ():), to obtain compound 17-A (2.16mg, 2.10%) and 17-A (4.81mg, 4.77%).
[0208] Compound 17-A
[0209] LCMS: (ESI, m / z): 519.25 [M+H] + .
[0210] 1H NMR (400MHz, DMSO-d6, ppm) δ9.06 (m, 1H), 8.12 (d, J = 5.1Hz, 1H), 7.39 (dd, J = 8.2, 1.9Hz, 1H), 7.34 (d, J = 1.8Hz, 1H), 6.70(d,J=8.2Hz,1H),5.98(t,J=6.5Hz,1H),5.83(d,J=8.5Hz,1H),5.70(s,1H),4.69(p,J=8.9Hz,2H),4.26(d,J=5 .9Hz,2H),3.83(s,3H),3.55(d,J=12.1Hz,1H),3.26(d,J=12.0Hz,2H),2.75(d,J=4.2Hz,6H),2.57(d,J=3.9Hz,2H) ,2.08(dd,J=11.4,4.2Hz,1H),1.79(d,J=10.0Hz,2H),1.73–1.61(m,2H),1.60–1.48(m,1H),1.38(q,J=11.8Hz,1H).
[0211] Compound 17-B
[0212] 1 H NMR(400MHz,DMSO-d6,ppm)δ8.56(m,1H),8.13(tt,J=5.7,2.8Hz,1H),7.51–7.37(m,1H),7.34(d,J=1.8Hz, 1H),6.70(d,J=8.3Hz,1H),6.02(d,J=3.0Hz,1H),5.99(s,1H),4.75(qd,J=8.8,4.9Hz,2H),4.27(s,2H),3. 99(dt,J=13.0,8.3Hz,1H),3.83(s,3H),3.09(t,J=4.2Hz,1H),2.93(dt,J=10.8,3.4Hz,3H),2.75(d,J=4.5 Hz,3H),2.66(d,J=1.6Hz,3H),2.28–2.10(m,1H),2.03–1.91(m,2H),1.88–1.77(m,1H),1.70–1.45(m,4H).
[0213] Using conditions similar to those in the above examples, the compounds listed in Table 4 were prepared. The structural characterization data of these compounds are listed in Table 4.
[0214] Table 4
[0215]
[0216]
[0217] Example 6
[0218]
[0219] Step 1: Synthesis of Compound 140-1
[0220] Under nitrogen protection, 4-(3-(3-bromo-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)propyl-2-alkynyl-1-yl)amino)-3-methoxy-N-methylbenzamide (compound 001-3, 300 mg, 0.674 mmol, 1 equiv), 1-tert-butyloxycarbonyl-4-aminopiperidine (269.9 mg, 1.348 mmol, 2 equiv), (SP-4-1)-[1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-1-[[[[[[[[[[[[[[[[[[[[[[[[[ ]-4,5-dichloro-1,3-dihydro-2H-imidazole-2-ylidene]dichloro(2-methylpyridine)palladium (56.68 mg, 0.067 mmol, 0.1 equiv), cesium carbonate (878.14 mg, 2.696 mmol, 4 equiv), dissolved in dioxane (6 mL), reacted at 100 ° C for 1 hour, after the reaction, the solvent was dried, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (1:1)) to give compound 140-1 (337 mg, 84.15%).
[0221] LCMS: (ESI, m / z): 565.20 [M+H] + .
[0222] Step 2: Synthesis of Compound 140-2
[0223] 4-(5-(3-(2-methoxy-4-(methylcarbamoyl)phenyl)amino)propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)aminopiperidine-1-carboxylic acid tert-butyl ester (Compound 140-1, 380 mg, 0.673 mmol, 1 equiv) was added to the reaction flask, and dichloromethane (4 mL) was added, and then trifluoroacetic acid (4 mL) was added. The reaction was carried out at room temperature for 1 hour. After the reaction was completed, the solvent was directly dried to obtain Compound 140-2 (900 mg, 230.31%), which was directly used for the next step.
[0224] LCMS: (ESI, m / z): 465.15 [M+H] + .
[0225] Step 3: Synthesis of Compound 140
[0226] 3-Methoxy-N-methyl-4-(3-piperidin-4-ylamino)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)prop-2-yn-1-yl)aminobenzamide (Compound 140-2, 120 mg, 0.258 mmol, 1 equiv), dimethylaminoacetaldehyde hydrochloride (63.85 mg, 0.516 mmol, 2 equiv) were added to the reaction flask, methanol (4 mL) was added to dissolve, a few drops of triethylamine were added to adjust the pH to neutral, the mixture was stirred at room temperature for 2 hours, sodium cyanoborohydride (32.47 mg, 0.516 mmol, 2 equiv) was added, the mixture was reacted at room temperature overnight, the solvent was dried after the reaction, and the crude product was purified by high performance liquid chromatography under the following conditions: (Chromatographic column specifications: XselectCSHTM Prep C18 5μm 30*150mm OBD; mobile phase A: water (0.05% trifluoroacetic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 5% B to 27% B, 10 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 9.6), to obtain compound 140 (14.25 mg, 10.01%).
[0227] LCMS: (ESI, m / z): 535.95 [M+H] + .
[0228] Using conditions similar to those in the above examples, the compounds listed in Table 5 were prepared. The structural characterization data of these compounds are listed in Table 5.
[0229] Table 5
[0230]
[0231]
[0232]
[0233] Example 7
[0234]
[0235] Step 1: Synthesis of Compound 146-2
[0236] At room temperature, tert-butyl 5-nitro-3,4-dihydro-1H-isoquinoline-2-carboxylate (compound 146-1, 300 mg, 1.078 mmol, 1 equiv) and methanol (3 mL) were added to a sample bottle, and a 4 mol / L hydrogen chloride solution in 1,4-dioxane (3 mL) was added dropwise at 0°C. The mixture was reacted at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure without further purification to obtain compound 146-2 (240 mg).
[0237] 1 H NMR (400MHz, DMSO-d6, ppm) δ9.27 (s, 1H), 7.97 (dd, J = 8.1, 1.4Hz, 1H), 7.63 (d, J = 7.3Hz ,1H),7.54(t,J=7.9Hz,1H),4.39(s,2H),3.38(t,J=6.2Hz,2H),3.20(t,J=6.2Hz,2H).
[0238] Step 2: Synthesis of compound 146-3
[0239] At room temperature, 5-nitro-1,2,3,4-tetrahydroisoquinoline (compound 146-2, 240 mg, 1.347 mmol, 1 equiv), methanol (3 mL), acetic acid (80.88 mg, 1.347 mmol, 1 equiv) and formaldehyde aqueous solution (80.88 mg, 2.694 mmol, 2 equiv) were added to the sample bottle, and the reaction was stirred for 30 minutes. Sodium triacetoxyborohydride (570.91 mg, 2.694 mmol, 2 equiv) was added and stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (3×30 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (1×40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (1:1)) to give compound 146-3 (200 mg, 77.25%).
[0240] LCMS: (ESI, m / z): 193.05 [M+H] + .
[0241] Step 3: Synthesis of Compound 146-4
[0242] At room temperature, 2-methyl-5-nitro-1,2,3,4-tetrahydroisoquinoline (compound 146-3, 200 mg, 1.040 mmol, 1 equiv), iron powder (290.53 mg, 5.200 mmol, 5 equiv), ammonium chloride (162.24 mg, 3.120 mmol, 3 equiv), ethanol (4 mL) and water (1 mL) were added to the sample bottle. The reaction was carried out at 65°C for 2 hours. After the reaction was completed, the reaction solution was cooled to room temperature, diluted with water (30 mL), filtered, and the filtrate was extracted with ethyl acetate (3×30 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (1×40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure without further purification to obtain compound 146-4 (130 mg, 77.01%).
[0243] LCMS: (ESI, m / z): 162.95 [M+H] + .
[0244] Step 3: Synthesis of Compound 146
[0245] At room temperature, 2-methyl-1,2,3,4-tetrahydroisoquinolin-5-amine (compound 146-4, 50 mg, 0.308 mmol, 1 equiv), 4-({3-[5-bromo-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]propyl-2-ynyl-1-amino)-3-methoxy-N-methylbenzamide (compound 001-3, 164.66 mg, 0.370 mmol, 1.2 equiv), (SP-4-1)-[1 ,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(2-methylpyridine)palladium (31.11 mg, 0.037 mmol, 0.1 equiv), cesium carbonate (401.66 mg, 1.232 mmol, 4 equiv) and 1,4-dioxane (2 mL), nitrogen was replaced, and the reaction was carried out at 100 ° C overnight. After the reaction was completed, the reaction mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate (3x 10mL), the organic phases were combined, backwashed with saturated sodium chloride solution (10mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by HPLC under the following conditions: (chromatographic column specifications: Sunfire C18 5μm, 30mm*150mm; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 18% B to 32% B in 10 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 7.35) to obtain the formate salt of compound 146 (13.9mg, 7.86%).
[0246] LCMS: (ESI, m / z): 527.15 [M+H] + .
[0247] 1H NMR (400MHz, DMSO-d6, ppm) δ8.09 (q, J=4.4Hz, 1H), 7.52 (d, J=6.4Hz, 2H), 7.40 (dd, J=8.2 ,1.9Hz,1H),7.34(d,J=1.9Hz,1H),6.98(t,J=7.9Hz,1H),6.73(d,J=8.3Hz,1H),6.55(d, J=7.5Hz,1H),6.15(s,1H),5.97(t,J=6.3Hz,1H),4.84(q,J=8.8Hz,2H),4.29(d,J=6.3Hz ,2H),3.84(s,3H),3.47(s,2H),2.75(d,J=4.5Hz,3H),2.65(d,J=3.8Hz,4H),2.34(s,3H).
[0248] Example 8
[0249]
[0250] Step 1: Synthesis of compound 78-2
[0251] Under nitrogen protection, at room temperature, a solution of 1-tert-butylformate 3-(aminomethyl)piperidine (compound 78-1, 1 g, 4.666 mmol, 1 equiv), formaldehyde (1.89 g, 23.330 mmol, 5 equiv, 37%) and sodium cyanoborohydride (1.47 g, 23.330 mmol, 5 equiv) in dichloromethane (10 mL) was stirred and reacted overnight. After the reaction was completed, the reaction mixture was treated with water (30 mL), and the reaction mixture was extracted with dichloromethane (2×30 mL). The organic phases were combined, backwashed with saturated sodium chloride (1×30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol (20:01)) to give compound 78-2 (400 mg, 35.37%).
[0252] LCMS: (ESI, m / z): 243.15 [M+H] + .
[0253] Step 2: Synthesis of compound 78-3
[0254] Under nitrogen protection, at room temperature, 1-tert-butylformate-3-[(dimethylamino)methyl]piperidine (compound 78-2, 100 mg, 0.413 mmol, 1 equiv) and a solution of hydrogen chloride in ethyl acetate (2 mL) and methanol (2 mL) were stirred and reacted overnight. The residue was concentrated under reduced pressure to give the hydrochloride salt of compound 78-3 (70 mg, 94.94%).
[0255] LCMS: (ESI, m / z): 142.95 [M+H] + .
[0256] Step 3: Synthesis of Compound 78
[0257] Under nitrogen protection, at 100 ° C, N, N-dimethyl-1-piperidin-3-methylamine (compound 78-3) hydrochloride (24.08 mg, 0.135 mmol, 1.50 equiv), 4-({3-[5-bromo-2-(2,2,2-trifluoroethyl) pyrazol-3-yl]propyl-2-ynyl-1-amino)-3-methoxy-N-methylbenzamide (compound 001-3, 40 mg, 0.090 mmol, 1.00 equiv), ( A solution of SP-4-1)-[1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(2-methylpyridine)palladium (7.56 mg, 0.009 mmol, 0.10 equiv) and cesium carbonate (117.09 mg, 0.359 mmol, 4.00 equiv) in 1,4-dioxane (2 mL) was stirred for overnight reaction. After the reaction was completed, the residue was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol (5:01)), and the crude product was purified by HPLC under the following conditions: (chromatographic column specifications: Xselect CSHTM Prep C18 5um 30×150mm OBD; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; gradient: 5% B to 35% B in 8 minutes; wavelength: UV 254nm / 221nm; retention time (minutes): 6.42) to give the formate salt of compound 78 (4.29 mg, 8.51%).
[0258] LCMS: (ESI, m / z): 507.25 [M+H] + .
[0259] Using conditions similar to those in the above examples, the compounds listed in Table 6 were prepared. The structural characterization data of these compounds are listed in Table 6.
[0260] Table 6
[0261]
[0262]
[0263] Example 9
[0264]
[0265] Step 1: Synthesis of Compound 148
[0266] Under nitrogen protection, at 100°C, a solution of 2-methyl-3,4-dihydro-1H-isoquinolin-7-ylboronic acid hydrochloride (compound 148-1, 33 mg, 0.145 mmol, 1 equiv), 4-({3-[5-bromo-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]propyl-2-ynyl-1-amino)-3-methoxy-N-methylbenzamide (compound 001-3, 51.67 mg, 0.116 mmol, 0.8 equiv), 1,1-bis(diphenylphosphino)ferrocenepalladium(II) chloride (11.82 mg, 0.014 mmol, 0.1 equiv) and potassium phosphate (92.37 mg, 0.435 mmol, 3 equiv) in 1,4-dioxane (3 mL) and water (0.6 mL) was stirred for reaction for 4 hours. After the reaction was completed, the residue was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane / methanol (5:1)), and the crude product was purified by high performance liquid chromatography under the following conditions: (chromatographic column specifications: YMC Triart C18 ExRs 5μm, 30mm×150mm; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 ml / min; gradient: 35% B to 58% B in 8 minutes; wavelength: UV 254nm / 220nm; retention time (minutes): 7.68) to obtain compound 148 (18.31 mg, 24.23%).
[0267] LCMS: (ESI, m / z): 512.30 [M+H] + .
[0268] 1 H NMR (400MHz, DMSO-d6, ppm) δ8.10(d,J=4.6Hz,1H),7.53(s,1H),7.51(d,J=1.8Hz,1H),7.41 (dd,J=8.3,1.9Hz,1H),7.35(d,J=2.0Hz,1H),7.07(d,J=7.8Hz,1H),7.03(s,1H),6.75(d,J =8.3Hz,1H),6.01(t,J=6.4Hz,1H),5.04(q,J=8.9Hz,2H),4.32(d,J=6.4Hz,2H),3.84(s,3H ),3.48(s,2H),2.88–2.80(m,2H),2.75(d,J=4.5Hz,3H),2.59(t,J=5.9Hz,2H),2.33(s,3H).
[0269] Using conditions similar to those in the above examples, the compounds listed in Table 7 were prepared. The structural characterization data of these compounds are listed in Table 7.
[0270] Table 7
[0271]
[0272]
[0273]
[0274]
[0275]
[0276] Example 10
[0277]
[0278] Step 1: Synthesis of compound 76-1
[0279] Under nitrogen protection, at 65°C, 4-({3-[5-bromo-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]propyl-2-ynyl-1-amino)-3-methoxy-N-methylbenzamide (compound 001-3, 143 mg, 0.321 mmol, 1 equiv), 2-aminophenylboronic acid pinacol ester (84.44 mg, 0.385, 1.2 equiv). [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (20.93 mg, 0.032 mmol, 0.1 equiv), potassium phosphate (204.52 mg, 0.963 mmol, 3.0 equiv) in water (1 mL) and 1,4-dioxane (5 mL) were stirred for 2 hours. After the reaction, the reaction mixture was quenched with water at room temperature and extracted with ethyl acetate (3×10 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (1×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate) to give compound 76-1 (100 mg, 68.06%).
[0280] LCMS: (ESI, m / z): 458.35 [M+H] + .
[0281] Step 2: Synthesis of compound 76
[0282] At room temperature, a solution of 4-((3-(3-(2-aminophenyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)propyl-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide (compound 76-1, 50 mg, 0.109 mmol, 1 equiv), N-methylpiperidone (24.74 mg, 0.218 mmol, 2 equiv) in anhydrous acetic acid (1 mL) and methanol (1 mL) was stirred for reaction for 1 hour, and then 2-methylpyridine borane complex (58.45 mg, 0.545 mmol, 5 equiv) was added in batches at room temperature. After the addition was completed, the reaction was stirred at 50°C for one hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the residue was purified by high performance liquid chromatography under the following conditions: (Chromatographic column specifications: XBridge BEH C18 OBD Prep Column 5μm, 30mm*150mm; mobile phase A: water (0.1% ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 35% B to 45% B in 10 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 9.48), to obtain compound 76 (3.87 mg, 6.15%).
[0283] LCMS: (ESI, m / z): 555.30 [M+H] + .
[0284] Embodiment 11
[0285]
[0286] Step 1: Synthesis of compound 88-2
[0287] 4-Chloropyrazole (compound 88-1, 1 g, 9.754 mmol, 1 equiv) and sodium hydroxide (1.56 g, 39.016 mmol, 4 equiv) were added to the reaction flask, dissolved in water (18 mL), and liquid bromine (3.90 g, 24.385 mmol, 2.5 equiv) was added dropwise at 0°C, and then the temperature was raised to room temperature to react overnight. After the reaction was completed, 2 mol / L hydrochloric acid was added to acidify, filtered, and the filter cake was washed with water several times to directly obtain compound 88-2 (1.28 g, 45.37%).
[0288] 1 H NMR (400MHz, DMSO-d6, ppm) δ14.33 (s, 1H).
[0289] Step 2: Synthesis of compound 88-3
[0290] 3,5-dibromo-4-chloro-1H-pyrazole (compound 88-2, 1 g, 3.842 mmol, 1 equiv), 2,2,2-trifluoroethyl trifluoromethanesulfonate (1.78 g, 7.684 mmol, 2 equiv), potassium carbonate (1.59 g, 11.526 mmol, 3 equiv), and N,N-dimethylformamide (10.0 mL) were added to the reaction flask for dissolution and reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench the reaction mixture, and the reaction mixture was extracted with ethyl acetate (3×20 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (20 mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (10:1)) to give compound 88-3 (1.4 g, 95.81%).
[0291] 1 H NMR (400MHz, DMSO-d6, ppm) δ5.25 (q, J=8.8Hz, 2H).
[0292] Step 3: Synthesis of Compound 88-4
[0293] Under argon protection, 3,5-dibromo-4-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole (compound 88-3, 920 mg, 2.687 mmol, 1 equiv), 3-methoxy-N-methyl-4-(prop-2-yn-1-ylamino)benzamide (586.54 mg, 2.687 mmol, 1 equiv), tetrakistriphenylphosphine palladium (310.55 mg, 0.269 mmol, 0.1 equiv), cuprous iodide (51.18 mg, 0.26 9mmol, 0.1equiv), diisopropylamine (2719.45mg, 26.870mmol, 10.0equiv), dimethyl sulfoxide (10.0mL) were dissolved, and the reaction was carried out at 100°C for 1 hour. After the reaction was completed, water was added to quench the reaction mixture, and the reaction mixture was extracted with ethyl acetate (3×10mL). The organic phases were combined, backwashed with saturated sodium chloride solution (1×10mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high performance liquid chromatography under the following conditions: (Chromatographic column specifications: XBridge BEH C18 OBDPrep Column 5μm, 30mm*150mm; mobile phase A: water (0.05% trifluoroacetic acid), mobile phase B: acetonitrile; flow rate: 100 ml / min; elution gradient: 35% B to 65% B, 20 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 19), to obtain compound 88-4 (120 mg, 9.28%).
[0294] 1 H NMR (400MHz, DMSO-d6, ppm) δ8.10(d,J=4.8Hz,1H),7.40(dd,J=8.3,1.9Hz,1H),7.34(d,J=1.9Hz,1H),6. 75(d,J=8.3Hz,1H),6.03(s,1H),5.09(q,J=8.8Hz,2H),4.37(s,2H),3.83(s,3H),2.75(d,J=4.4Hz,3H).
[0295] Step 4: Synthesis of Compound 88
[0296] Under nitrogen protection, the reaction flask was added with 4-(3-(3-bromo-4-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)propyl-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide (compound 88-4, 100 mg, 0.208 mmol, 1 equiv), N,N-dimethyl-1,4-cyclohexanediamine (59.31 mg, 0.416 mmol, 2 equiv), (SP-4-1)-[1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H -imidazole-2-ylidene]dichloro(2-methylpyridine)palladium (17.54 mg, 0.021 mmol, 0.1 equiv), cesium carbonate (271.7 mg, 0.834 mmol, 4.00 equiv), dioxane (5 mL) were dissolved, reacted at 100 ° C for 1 hour, and after the reaction was completed, water was added to quench the reaction mixture. The reaction mixture was extracted with ethyl acetate (3×10 mL), the organic phases were combined, backwashed with saturated sodium chloride solution (1×5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions: (Chromatographic column specifications: Sunfire C18 5μm, 30mm*150mm; mobile phase A: water (0.05% formic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 10% B to 33% B, 8 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 6.63), to obtain compound 88 (4.15 mg, 3.67%).
[0297] LCMS: (ESI, m / z): 541.15 [M+H] + .
[0298] Example 12
[0299]
[0300] Step 1: Synthesis of compound 86-2
[0301] 3,4,5-tribromo-1H-pyrazole (compound 86-1, 1 g, 3.281 mmol, 1 equiv) and tetrahydrofuran (10 mL) were added to the reaction flask to dissolve, and the temperature was lowered to -78 ° C. Then, n-butyl lithium (1.45 mL, 3.609 mmol, 2.5 M n-hexane solution, 1.1 equiv) was added, and the mixture was stirred for 30 minutes. Then, iodomethane (465.73 mg, 3.281 mmol, 1 equiv) was added, and the reaction was continued at -78 ° C for 1 hour. The mixture was warmed to room temperature and saturated ammonium chloride solution was added to quench the reaction mixture. The reaction mixture was extracted with ethyl acetate (3×10 mL), and the organic phases were combined, backwashed with saturated sodium chloride solution (10 mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to directly obtain compound 86-2 (738 mg, 46.88%).
[0302] 1 H NMR (400MHz, DMSO-d6, ppm) δ13.69 (s, 1H), 1.90 (s, 3H).
[0303] Step 2: Synthesis of compound 86-3
[0304] 3,5-dibromo-4-methyl-1H-pyrazole (compound 86-2, 300 mg, 0.984 mmol, 1 equiv), 2,2,2-trifluoroethyl trifluoromethanesulfonate (429.33 mg, 1.968 mmol, 2 equiv), potassium carbonate (408.13 mg, 2.952 mmol, 3 equiv), and N,N-dimethylformamide (3.0 mL) were added to the reaction flask for dissolution and reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench the reaction mixture, and the reaction mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (10 mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (10:1)) to give compound 86-3 (300 mg, 93.72%).
[0305] 1 H NMR (400MHz, DMSO-d6, ppm) δ5.13 (q, J = 8.8Hz, 2H), 1.96 (s, 3H).
[0306] Step 3: Synthesis of Compound 86-4
[0307] Under argon protection, 3,5-dibromo-4-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole (compound 86-3, 320 mg, 0.994 mmol, 1 equiv), 3-methoxy-N-methyl-4-propyl-2-alkynylaminobenzamide (compound 001-2A, 216.95 mg, 0.994 mmol, 1 equiv), tetrakistriphenylphosphine palladium (114.87 mg, 0.099 mmol, 0. 1equiv), cuprous iodide (18.93 mg, 0.099 mmol, 0.1 equiv), diisopropylamine (1.01 g, 9.940 mmol, 10 equiv), dimethyl sulfoxide (5 mL) were dissolved, and the reaction was carried out at 80 ° C for 1 hour. After the reaction was completed, water was added to quench the reaction mixture, and the reaction mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (10 mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by high performance liquid chromatography under the following conditions: (chromatographic column specifications: XselectCSHTM Prep C18 5μm 30*150mm OBD; mobile phase A: water (0.05% trifluoroacetic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 35% B to 50% B, 10 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 8.93) to obtain compound 86-4 (41 mg, 8.99%).
[0308] 1 H NMR (400MHz, DMSO-d6, ppm) δ8.08 (q, J=4.6Hz, 1H), 7.40 (dd, J=8.2, 1.9Hz, 1H), 7.34 (d, J=1.9Hz, 1H), 6.75 (d, J=8.3Hz,1H),5.97(s,1H),4.98(q,J=8.9Hz,2H),4.33(s,2H),3.83(s,3H),2.75(d,J=4.4Hz,3H),1.92(s,3H).
[0309] Step 3: Synthesis of Compound 86
[0310] The reaction flask was added with 4-(3-(3-bromo-4-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)propyl-2-yn-1-ylamino-3-methoxy-N-methylbenzamide (compound 86-4, 40 mg, 0.087 mmol, 1 equiv), N,N-dimethyl-1,4-cyclohexanediamine (24.78 mg, 0.174 mmol, 2 equiv), (SP-4-1)-[1,3-bis[2,6-bis(1- [ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazole-2-ylidene]dichloro(2-methylpyridine)palladium (7.33 mg, 0.009 mmol, 0.1 equiv), cesium carbonate (113.51 mg, 0.348 mmol, 4 equiv), 1,4-dioxane (2 mL) was added to dissolve, and the mixture was reacted at 100 ° C for 2 hours. After the reaction, the solvent was dried by spin drying, and the crude product was successively prepared by high performance liquid chromatography under the following conditions (chromatographic column specifications: Xselect CSHTM Prep C18 5μm30*150mm OBD; mobile phase A: water (0.05% trifluoroacetic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 10% B to 30% B, 10 min; detection wavelength: UV254nm / 220nm; retention time (min): 9.62), chiral HPLC purification, conditions are as follows (chromatographic column specifications: CHIRALART Cellulose-SC 2*25cm, 5μm; mobile phase A: n-hexane (0.1% diethylamine), mobile phase B: methanol: dichloromethane = 1:1; flow rate: 20 ml / min; gradient: isocratic 25; detection wavelength: UV 254 / 220nm; front peak retention time 1 (min): 12.33; rear peak retention time 2 (min): 16.18; sample solvent: methanol; injection volume: 1.0 mL; number of runs: 1), to obtain compounds 86-A (front peak, 1.02 mg, 2.25%) and 86-B (rear peak, 1.28 mg, 2.82%).
[0311] Compound 86-A
[0312] LCMS: (ESI, m / z): 521.20 [M+H] + .
[0313] 1H NMR(400MHz,DMSO-d6,ppm)δ8.09(q,J=4.5Hz,1H),7.39(dd,J=8.2,1.8Hz,1H),7.34(d,J=1.9Hz ,1H),6.72(d,J=8.2Hz,1H),5.95(t,J=6.3Hz,1H),4.75(d,J=6.8Hz,1H),4.63(q,J=8.9Hz,2H), 4.28(d,J=6.3Hz,2H),3.83(s,3H),3.45(s,1H),2.75(d,J=4.5Hz,3H),2.19(s,6H),2.10–2.05( m,1H),1.80(s,3H),1.70(dd,J=11.4,6.9Hz,4H),1.53(dt,J=8.2,4.6Hz,2H),1.46–1.38(m,2H).
[0314] Compound 86-B
[0315] LCMS: (ESI, m / z): 521.20 [M+H] + .
[0316] 1 H NMR (400MHz, DMSO-d6, ppm) δ8.08(q,J=4.4Hz,1H),7.39(dd,J=8.2,1.9Hz,1H),7.34(d,J=1.9Hz,1 H),6.72(d,J=8.2Hz,1H),5.95(t,J=6.3Hz,1H),4.82(d,J=7.7Hz,1H),4.63(q,J=8.9Hz,2H),4.28 (d,J=6.3Hz,2H),3.83(s,3H),3.18(dt,J=7.4,3.7Hz,1H),2.75(d,J=4.5Hz,3H),2.28(s,1H),2.2 4(s,6H),2.04(d,J=11.9Hz,2H),1.77(s,5H),1.23(d,J=11.5Hz,2H),1.13(q,J=12.7,12.3Hz,2H).
[0317] Using conditions similar to those in the above examples, the compounds listed in Table 8 were prepared. The structural characterization data of these compounds are listed in Table 8.
[0318] Table 8
[0319]
[0320] Embodiment 13
[0321]
[0322] Step 1: Synthesis of compound 12-2
[0323] At room temperature, 5-bromo-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxylic acid methyl ester (compound 12-1, 150 mg, 0.523 mmol, 1 equiv), 3-methoxy-N-methyl-4-propyl-2-alkynylaminobenzamide (compound 001-2A, 136.87 mg, 0.628 mmol, 1.2 equiv), cuprous iodide (9.95 mg, 0.052 mmol, 0.1 equiv), tetrakis(triphenylphosphine)palladium (60.39 mg, 0.0 52mmol, 0.1equiv) and diisopropylamine (528.82mg, 5.230mmol, 10equiv), replace nitrogen, stir at 50°C for 1 hour, after the reaction is completed, add water to quench, the reaction mixture is extracted with ethyl acetate (3×5mL), the organic phases are combined, backwashed with saturated sodium chloride solution (5mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography (petroleum ether / ethyl acetate (1:1)) to give compound 12-2 (130mg, 58.62%).
[0324] LCMS: (ESI, m / z): 425.05 [M+H] + .
[0325] Step 2: Synthesis of compound 12-3
[0326] At room temperature, 5-(3-{[2-methoxy-4-(methylcarbamoyl)phenyl]amino}propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxylic acid methyl ester (compound 12-2, 300 mg, 0.707 mmol, 1 equiv), tetrahydrofuran (3 mL), water (3 mL) and lithium hydroxide (33.86 mg, 1.414 mmol, 2 equiv) were added to the reaction bottle, and the reaction was stirred at 50 ° C for 1 hour. After the reaction, the reaction mixture was quenched with water at room temperature and extracted with ethyl acetate (3×10 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (1×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure without further purification to obtain compound 12-3 (250 mg, 86.18%).
[0327] LCMS: (ESI, m / z): 411.00 [M+H] + .
[0328] Step 2: Synthesis of compound 12
[0329] At room temperature, 5-(3-{[2-methoxy-4-(methylcarbamoyl)phenyl]amino}propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxylic acid (compound 12-3, 90 mg, 0.219 mmol, 1 equiv), 4-amino-1-methylpiperidine (37.57 mg, 0.329 mmol, 1.5 equiv), dichloromethane (4 mL) and N,N-diisopropylethylamine (85.04 mg, 0.657 mmol, 3 equiv) were added to the sample vial. The reaction was stirred for 20 minutes, 1-propylphosphoric acid tricyclic anhydride (75.71 mg, 0.329 mmol, 1.5 equiv) was added, and the reaction was allowed to react at room temperature for 2 hours. After the reaction was completed, the reaction mixture was quenched with water at room temperature, extracted with ethyl acetate (3×10 mL), the organic phases were combined, backwashed with saturated sodium chloride solution (10 mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography under the following conditions: (chromatographic column specifications: Sunfire C18 5μm, 30mm*150mm; mobile phase A: water (0.1% formic acid), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 15% B to 35% B in 8 minutes; detection wavelength: UV 254nm / 220nm; retention time (minutes): 7.22), secondary preparation, the conditions are as follows (chromatographic column specifications: Sunfire C18 5μm, 30mm*150mm; mobile phase A: water (0.1% ammonium bicarbonate), mobile phase B: acetonitrile; flow rate: 60 ml / min; elution gradient: 15% B to 35% B in 8 minutes; detection wavelength: UV254nm / 220nm; retention time (minutes): 7.11), to obtain compound 12 (27.58 mg, 19.54%).
[0330] LCMS: (ESI, m / z): 507.25 [M+H] + .
[0331] 1H NMR(400MHz,DMSO-d6,ppm)δ8.10(q,J=4.5Hz,1H),7.99(d,J=8.1Hz,1H),7.40(dd,J=8.2,1.8Hz,1H),7 .34(d,J=1.9Hz,1H),6.90(s,1H),6.74(d,J=8.3Hz,1H),6.00(t,J=6.4Hz,1H),5.05(q,J=8.8Hz,2H),4 .31(d,J=6.4Hz,2H),3.83(s,3H),3.67(dtt,J=11.3,8.4,4.4Hz,1H),2.75(d,J=4.5Hz,3H),2.71(d,J= 2.8Hz,2H),2.13(s,3H),1.90(td,J=11.6,2.7Hz,2H),1.72–1.63(m,2H),1.57(td,J=11.9,3.8Hz,2H).
[0332] Embodiment 14
[0333]
[0334] Step 1: Synthesis of compound 5-2
[0335] Under nitrogen protection, at room temperature, a solution of dimethyl butynedioate (8.37 g, 58.910 mmol, 1.2 eq) in toluene (70 mL) was added dropwise with 2,2,2-trifluoroethylhydrazine (compound 5-1, 5.6 g, 49.092 mmol, 1 eq) and acetic acid (42 mL). The solution was stirred at 40 ° C for overnight reaction. After the reaction was completed, the reaction mixture was quenched with water at room temperature. The reaction mixture was extracted with ethyl acetate (3 × 100 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (3 × 100 mL), and dried over anhydrous sodium sulfate. After the obtained mixture was filtered, the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography, petroleum ether / ethyl acetate (1:1) to obtain compound 5-2 (7 g, 63.62%).
[0336] LCMS: (ESI, m / z): 225.00 [M+H] + .
[0337] Step 2: Synthesis of compound 5-3
[0338] Under nitrogen protection, at 80°C, a solution of 5-hydroxy-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxylic acid methyl ester (compound 5-2, 600 mg, 2.677 mmol, 1 eq) and tribromophosphine oxide (3.07 g, 10.708 mmol, 4 eq) in acetonitrile (6 mL) was stirred for 24 hours. After the reaction was completed, the reactants were concentrated under reduced pressure and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (9:1)) to give compound 5-3 (0.5 g, 65.07%).
[0339] LCMS: (ESI, m / z): 286.90 [M+H] + .
[0340] Step 3: Synthesis of compound 5-4
[0341] Under nitrogen protection, at -78°C, 2.5 mol / L lithium diisopropylaluminum hydride toluene solution (545.02 mg, 3.832 mmol, 2.00 eq) was added dropwise to a solution of 5-bromo-1-(2,2,2-trifluoroethyl)-1H-pyrazole-3-carboxylic acid methyl ester (compound 5-3, 550 mg, 1.916 mmol, 1 eq) in dichloromethane (5.5 mL) and the reaction system was reacted at 0°C for 1 hour. After the reaction, ether (50 mL) was added to dilute the reaction mixture at room temperature, and sodium sulfate decahydrate was added to the reaction mixture at room temperature to quench. The filter cake was washed with ethyl acetate (2×10 mL), and the filtrate was concentrated under reduced pressure to obtain compound 5-4 (280 mg, 56.41%).
[0342] LCMS: (ESI, m / z): 258.85 [M+H] + .
[0343] Step 4: Synthesis of compound 5-5
[0344] At room temperature, a solution of [5-bromo-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]methanol (compound 5-4, 280 mg, 1.081 mmol, 1 eq) and Dess-Martin (916.97 mg, 2.162 mmol, 2 eq) in dichloromethane (5 mL) was stirred for 1 hour. After the reaction was completed, the residue was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (3:1)) to give compound 5-5 (200 mg, 71.99%).
[0345] LCMS: (ESI, m / z): 256.85 [M+H] + .
[0346] Step 5: Synthesis of compound 5-6
[0347] At 50°C, a solution of 5-bromo-1-(2,2,2-trifluoroethyl)pyrazole-3-carboxaldehyde (compound 5-5, 240 mg, 0.934 mmol, 1 eq) and 1-methylpiperidin-4-amine (213.27 mg, 1.868 mmol, 2.00 eq) in methanol (5 mL) was stirred and reacted overnight. Sodium borohydride (70.65 mg, 1.868 mmol, 2 eq) was added to the above system in batches at 0°C and stirring was continued for 1 hour. After the reaction was completed, a saturated aqueous sodium bicarbonate solution (30 mL) was added to the reaction mixture at room temperature to quench it. The reaction mixture was extracted with dichloromethane (2×30 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol (1:1)) to give compound 5-6 (200 mg, 60.30%).
[0348] LCMS: (ESI, m / z): 355.00 [M+H] + .
[0349] Step 6: Synthesis of compound 5
[0350] Under nitrogen protection, at 70°C, a solution of N-([5-bromo-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]methyl-1-methylpiperidin-4-amine (compound 5-6, 30 mg, 0.084 mmol, 1 eq), 3-methoxy-N-methyl-4-(propyl-2-yn-1-ylamino)benzamide (18.43 mg, 0.084 mmol, 1 eq), tetrakistriphenylphosphine palladium (9.76 mg, 0.008 mmol, 0.1 eq), cuprous iodide (1.61 mg, 0.008 mmol, 0.1 eq) and diisopropylamine (85.47 mg, 0.840 mmol, 10 eq) in tetrahydrofuran (2 mL) was stirred and reacted overnight. After the reaction was completed, the mixture was filtered, the filter cake was washed with ethyl acetate (2×5 mL), the filtrate was concentrated under reduced pressure, and the crude product was purified by high performance liquid chromatography under the following conditions (chromatographic column specifications: Kinete x 5m EVO C18, 30mm x 150mm; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile: flow rate: 60 ml / min; gradient: 5% B to 40% B in 10 minutes; detection wavelength: 254nm / 220nm; retention time (minutes): 9.03), to obtain compound 5-6 (4.6 mg, 10.87%).
[0351] LCMS: (ESI, m / z): 493.05 [M+H] + .
[0352] 1H NMR (400MHz, DMSO-d6, ppm) δ8.12 (q, J=4.5Hz, 1H), 7.39 (dd, J=8.2, 1.9Hz, 1H), 7.33 (d ,J=1.9Hz,1H),6.72(d,J=8.2Hz,1H),6.48(s,1H),6.01(t,J=6.3Hz,1H),4.92(d,J=9. 0Hz,2H),4.28(d,J=6.3Hz,2H),3.83(s,3H),3.61(s,2H),2.74(d,J=4.4Hz,3H),2.64( d,J=10.1Hz,2H),2.25(s,1H),2.09(s,3H),1.79-1.70(m,5H),1.19(d,J=11.4Hz,2H).
[0353] Using conditions similar to those in the above examples, the compounds listed in Table 9 were prepared. The structural characterization data of these compounds are listed in Table 9.
[0354] Table 9
[0355]
[0356] Biological evaluation
[0357] Test Example 1: In vitro DNA binding activity assay
[0358] Time-Resolved Fluorescence Resonance Energy Transfer (TR-FREt) was used to detect the activity of compounds regulating the binding of Y220C to DNA. First, the recombinant Y220C p53 DBD protein with his-tag and the DNA sequence labeled with biotin were prepared. The donor Eu(Europium)-SA(Streptavidin) can bind to the DNA sequence through biotin, and the acceptor is the his antibody connected to allophycocyanin (APC, allophycocyanin), and the his antibody can bind to the Y220C p53 DBD protein with his-tag. When given an excitation light of 340nm wavelength, the donor Eu(Europium)-SA(Streptavidin) will produce fluorescence with an emission wavelength of 620nm. If the donor and the acceptor are close to each other, the donor will transfer part of the energy to the acceptor, producing fluorescence with an emission wavelength of 665nm. That is to say, if the p53 mutant protein is reactivated by the compound and binds to DNA, the donor energy is transferred to the acceptor, which will produce fluorescence at 615 and 665nm. If there is no interaction, only fluorescence at 615nm will be produced.
[0359] a. Add 4 μL of diluted compound solution to each well of a 384-well microplate.
[0360] b. Add 4 μL of 4X P53 working solution to each well of a 384-well microplate.
[0361] c. Seal the 384-well microplate and equilibrate at room temperature for 60 minutes.
[0362] d. Add 4 μl of biotinylated DNA solution into a 384-well microplate.
[0363] e. Add 4 μl of 4X detection solution (MAb Anti-6His-Eu and Streptavidin-d2) to each well of a 384-well microplate.
[0364] f. Incubate overnight, protected from light.
[0365] g. Read the data of 665nm and 615nm wavelengths on BMG.
[0366] The representative compounds in this article were tested for their reactivation activity on p53-Y220C mutant protein by the above experiment. 150 See Table 10 for values.
[0367] Table 10 SC activity of representative compounds in this article on p53-Y220C mutant protein 150 value
[0368]
[0369]
[0370]
[0371] Note: SC 150 Indicates the concentration of compound required to increase protein-DNA binding activity by 50%
[0372] Experimental conclusion: The above representative compounds can effectively restore the activity of p53-Y220C mutant protein.
[0373] The above is an exemplary description of the implementation of the technical solution of the present invention. It should be understood that the protection scope of the present invention is not limited to the above implementation. Any modification, equivalent substitution, improvement, etc. made by those skilled in the art within the spirit and principle of the present invention should be included in the protection scope of the claims of this application.
Claims
1. A compound represented by formula (I) and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt: in, R 1 , R 2 are the same or different and are independently selected from H, deuterium, halogen, C 1-12 Alkyl, C 1-12 Alkoxy; R 3 Selected from H, deuterium, C 1-12 alkyl; X 1 Selected from NR x11 , CR x12 ; X 2 Selected from NR x21 , CR x22 , O, S; X 4 Selected from NR x41 , CR x42 , O, S; R x11 , R x21 , R x41 does not exist; or R x11 , R x21 , R x41 The same or different, independently selected from H, C 1-12 Alkyl, halogenated C 1-12 Alkyl, C 3-12 Cycloalkyl; R x12 , R x22 , R x42 are the same or different and are independently selected from H, halogen, cyano, aldehyde, carboxyl, C 1-12 Alkyl, C 2-12 Alkenyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, halogenated C 1-12 Alkyl, cyano C 1-12 Alkyl, halogenated C 2-12 Alkenyl, halogenated C 1-12 Alkoxy, halogenated C 3-12 Cycloalkyl, -C(O)OC 1-12 Alkyl, -C(O)NH 2 ; X 3 Selected from C or N; represents a single or double bond; Ring A is selected from C 6-14 Aromatic ring, 5-14 membered heteroaromatic ring, 3-14 membered heterocyclic ring; Y is absent or selected from -C(=O)-R y1 、-S(=O)-R y2 、-S(=O) 2 -R y3 ,-P(=O)(R y4 )(R y5 )、-S(=O)(=NR y6 )-R y7 、-C(=O)NH-R y8 , R y9 Substituted 5-14 membered heteroaryl; R y1 , R y2 , R y3 , R y4 , R y5 , R y6 , R y7 , R y8 , R y9 are the same or different and are independently selected from H, deuterium, unsubstituted or optionally substituted by one, two or more R y Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 1-12 Alkyl-NH-, (C 1-12 alkyl) 2 N-、NH 2 or, R y4 and R y5 and the P atom to which it is connected form an unsubstituted or optionally substituted with one, two or more R y substituted 3-14 membered heterocyclic group; or, R y6 and R y7 and the atoms to which they are attached form unsubstituted or optionally substituted with one, two or more R y substituted 3-14 membered heterocyclic group; or, R y7 The S atom to which it is connected forms a 3-14-membered heterocyclic group fused to ring A; Each R y are the same or different and are independently selected from H, deuterium, halogen, cyano, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, -C(=O)-C 1-12 Alkyl, -C(=O)-C 3-12 Cycloalkyl; Each R a are the same or different and are independently selected from H, deuterium, cyano, halogen, oxo (=O), unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, OH, NH 2 ; Each R a1 are the same or different and are independently selected from H, deuterium, cyano, oxo (=O), halogen, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy; m is selected from 0, 1, 2, 3, 4 or 5; Or, Y and an R a The atoms to which they are attached form unsubstituted or optionally substituted with one, two or more R a1 substituted 3-14 membered heterocyclic group; Z does not exist (i.e. R z Directly with X 3 bond chain) or selected from NH, O, S, CH 2 , CH 2 N(R z0 )、C(O)NH;R z0 Select from H or C 1-12 alkyl; R z is selected from unsubstituted or optionally substituted with one, two or more R z1 Substituted with the following groups: C 1-12 Alkyl, C 6-14 Aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclic group, C 3-12 Cycloalkyl; each R z1 are the same or different and are independently selected from H, deuterium, OH, cyano, oxo (=O), halogen, unsubstituted or optionally substituted by one, two or more R z2 Substituted with the following groups: CH 2 =, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, NH 2 ; Each R z2 are the same or different and are independently selected from H, deuterium, OH, cyano, oxo (=O), halogen, unsubstituted or optionally substituted by one, two or more R z3 Substituted with the following groups: C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, 3-14 membered heterocyclic group, S(O) 2 C 1-12 Alkyl, NH 2 ; Each R z3 are the same or different and are independently selected from H, deuterium, OH, cyano, oxo (=O), halogen, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, C 1-12 Alkyl-NH-, (C 1-12 alkyl) 2 N-、NH 2 .
2. The compound according to claim 1 and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, It is characterized in that R 1 , R 2 , R 3 The same or different, independently selected from H, C 1-6 alkyl; Preferably, R 1 , R 2 , R 3 All are H; Preferably, when X 1 Selected from NR x11 When X 2 Selected from CR x22 , N, X 4 Selected from CR x42 , N; when X 1 Selected from CR x12 When X 2 Selected from N, O, S, X 4 Selected from N, S, O; Preferably, R x11 , R x21 , R x41 does not exist; or R x11 , R x21 , R x41 The same or different, independently selected from H, C 1-6 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl; R x12 , R x22 , R x42 are the same or different and are independently selected from H, cyano, halogen, carboxyl, aldehyde, C 1-6 Alkyl, C 2-6 Alkenyl, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, cyano C 1-6 Alkyl, halogenated C 2-6 Alkenyl, C 3-8 Cycloalkyl, -C(O)OC 1-6 Alkyl, -C(O)NH 2 ; Preferably, R x11 , R x21 , R x41 does not exist; or R x11 , R x21 , R x41 are the same or different and are independently selected from H, methyl, ethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl, cyano; Preferably, R x21 , R x41 Does not exist; R x11 It is 2,2,2-trifluoroethyl; Preferably, R x12 , R x22 , R x42 are the same or different and are independently selected from H, methyl, ethyl, F, Cl, difluoromethyl, cyano, cyanomethylene, aldehyde, carboxyl, -C(O)OCH 3 、-C(O)NH 2 , 2,2,2-trifluoroethyl, cyclopropyl, vinyl, Preferably, R x12 is 2,2,2-trifluoroethyl; R x22 Selected from H, methyl, ethyl, F, Cl, aldehyde, difluoromethyl, cyano, cyanomethylene, -C(O)OCH 3 、-C(O)NH 2 ; R x42 Selected from H, methyl, cyano, carboxyl, -C(O)OCH 3 , cyclopropyl, vinyl, 3. The compound according to claim 1 or 2, and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, It is characterized in that Ring A is selected from C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring, 5-10 membered heterocyclic ring; Preferably, ring A is selected from a benzene ring, a pyridine ring, a benzothiophene ring, a benzothiazole ring, a benzofuran ring, and a 2,3-dihydrobenzofuran ring; Preferably, ring A is selected from a benzene ring, a benzothiophene ring, a benzothiazole ring, a benzofuran ring, and a 2,3-dihydrobenzofuran ring.
4. A compound according to any one of claims 1 to 3 and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, It is characterized in that Y is selected from -C(=O)-R y1 、-S(=O)-R y2 、-S(=O) 2 -R y3 ,-P(=O)(R y4 )(R y5 )、-S(=O)(=NR y6 )-R y7 、-C(=O)NH-R y8 , R y9 Substituted 5-8 membered heteroaryl; R y1 , R y2 , R y3 , R y4 , R y5 , R y6 , R y7 , R y8 , R y9 are the same or different and are independently selected from H, unsubstituted or optionally substituted with one, two or more R y Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, C 1-6 Alkyl-NH-, (C 1-6 alkyl) 2 N-、NH 2 or, R y4 and R y5 and the P atom to which it is connected form an unsubstituted or optionally substituted with one, two or more R y Substituted 3-6 membered heterocycle; Preferably, each R y are the same or different and are independently selected from H, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, -C(=O)-C 1-6 Alkyl, -C(=O)-C 3-8 Cycloalkyl; Preferably, R y1 , R y2 , R y3 , R y4 , R y5 , R y6 , R y7 , R y8 , R y9 are the same or different and are independently selected from H, methyl, ethyl, isopropyl, cyclopropyl, methylamino, NH 2 , piperidinyl, tetrahydropyranyl, piperazinyl, cyanomethyl, 2,2,2-trifluoroethyl; or, R y4 and R y5 and the P atom to which it is connected form an unsubstituted or optionally substituted with one, two or more R y Replaced Preferably, each R y are the same or different and are independently selected from H, F, cyano, methyl, ethyl, methoxy, cyclopropyl, acetyl, cyclopropanecarboxyl; Preferably, Y is selected from Preferably, Y and one R a The atoms to which they are attached form unsubstituted or optionally substituted with one, two or more R a1 Substituted 3-8 membered heterocycle; for example Preferably, each R a are the same or different and are independently selected from cyano, halogen, unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, OH, NH 2 ; Each R a1 are the same or different and are independently selected from H, cyano, oxo (=O), halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy; Preferably, each R a are the same or different and are independently selected from H, cyano, halogen, unsubstituted or optionally substituted by one, two or more R a1 Substituted with the following groups: C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, OH, NH 2 ; Each R a1 are the same or different and are independently selected from H, cyano, oxo (=O), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl, halogenated C 1-3 Alkyl, halogenated C 1-3 Alkoxy; Preferably, each R a are the same or different and are independently selected from H, fluorine, chlorine, methoxy, trifluoromethoxy, difluoromethoxy, monofluoromethoxy, cyclopropyloxy, difluoromethyl, trifluoromethyl, Preferably, m is selected from 1 or 2; Preferably, m is 1.
5. The compound according to any one of claims 1 to 4 and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, It is characterized in that ring is selected from a five-membered heteroaromatic ring containing at least one nitrogen atom; Preferably, the ring is selected from a pyrazole ring, a pyrrole ring, an imidazole ring, a thiazole ring, and an oxazole ring; Preferably, Z is absent or selected from NH, O, S, CH 2 , CH 2 N(CH 3 )、C(O)NH、CH 2 NH; Preferably, R z is selected from unsubstituted or optionally substituted with one, two or more R z1 Substituted with the following groups: C 1-6 Alkyl, 5-10 membered heterocyclic group, C 5-10 Cycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl; Preferably, R z is selected from unsubstituted or optionally substituted with one, two or more R z1 Substituted with the following groups: ethyl, propyl, phenyl, piperidinyl, cyclohexyl, Preferably, each R z1 are the same or different and are independently selected from hydrogen, F, Cl, methyl, methoxy, cyano, cyanomethyl, dimethylamino, oxo (=O), amino, methylamino, ethylamino, diethylamino, hydroxyl, CH 2 =, CHF =, CF 2 =、 Preferably, R z Selected from 6. A compound according to any one of claims 1 to 5 and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, It is characterized in that The compound represented by formula (I) has the structure shown below: Among them, ring A, Y, Z, R a , R z , R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , X 4 , m has the definition as described in any one of claims 1-5; Preferably, the compound represented by formula (I) has the structure shown below: Among them, ring A, Y, Z, R a , R z , R 1 , R 2 , R 3 , R 11 , R 12 , X 2 , X 4 , m has the definition as described in any one of claims 1-5; Preferably, the compound represented by formula (I) has the structure shown below: Among them, Y, Z, R a , R z , R 1 , R 2 , R 3 , R 11 , R 12 , X 2 , X 4 , m has the definition as described in any one of claims 1-5; Preferably, the compound represented by formula (I) has the structure shown below: Among them, Z, R z , R 1 , R 2 , R 3 , R 11 , X 2 It has the definition as described in any one of claims 1 to 5.
7. A compound according to any one of claims 1 to 6 and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, It is characterized in that The compound represented by formula (I) is selected from:
8. A method for preparing a compound according to any one of claims 1 to 7 and its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, The following steps are involved: (1) Compound 1 reacts with compound 2 to obtain compound 3; (2) Compound 3 and R z -ZH reaction to obtain a compound represented by formula (I); Ring A, Y, Z, R a , R z , R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , X 4 , m has the definition as described in any one of claims 1-7; L 1 and L 2 Selected from leaving groups, such as halogen, such as L 1 Selected from Br, L 2 Selected from Br.
9. A pharmaceutical composition comprising a therapeutically effective amount of at least one of the compound of any one of claims 1 to 7, its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof.
10. Use of at least one of the compound according to any one of claims 1 to 7, its racemate, stereoisomer, tautomer, nitrogen oxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof in the preparation of a medicament; Preferably, the use may be for preparing a drug for treating a tumor containing a p53-Y220C mutant, such as for preparing a drug for treating a p53-Y220C reactivator; Preferably, the tumor containing the p53-Y220C mutant includes acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancer, AIDS-related lymphoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumors such as cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive cell tumor, neuroectodermal tumor, visual pathway and hypothalamic glioma, breast cancer, bronchial adenoma, Burkitt's lymphoma, unknown primary cancer, central nervous system lymphoma, cerebellar astrocytoma, uterine Cervical cancer, childhood cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative diseases, colon cancer, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, germ cell tumors, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gliomas, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular carcinoma, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, lip cancer and oral cancer, liposarcoma, liver cancer, lung cancer such as non-small cell lung cancer and small cell lung cancer, lymphoma leukemia, macroglobulinemia, malignant fibrous histiocytoma of bone / osteosarcoma, medulloblastoma, melanoma, mesothelioma, metastatic squamous cell carcinoma with occult primary, oral cancer, multiple endocrine neoplasms syndrome, myelodysplastic syndrome, myeloid leukemia, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma / malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer, pancreatic islet cell carcinoma, paranasal sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal gland Astrocytoma, pineal germ cell tumor, pituitary adenoma, pleuropulmonary blastoma, plasmacytoma, primary central nervous system lymphoma, prostate cancer, colorectal cancer, renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer, Merkel cell carcinoma of the skin, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, laryngeal cancer, thymoma, thymic carcinoma, thyroid cancer, trophoblastic tumor (pregnancy), cancer of unknown primary site, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, and Wilms' tumor.
Citation Information
Cited By
Compound with p53 agonist activity, agonist and application thereof
CN119823116A
Compound, preparation method therefor and use thereof
WO2026138948A1
Use of small-molecule reactivator compound in preparation of Anti-tumor drug
WO2026138950A1
